Adverse Event,Category,Trial Id,URL,Condition,Intervention,Total-affected,Total-at risk,Serious/Other,Arm#,Arm Title,Arm-affected,Arm-at risk
Drug_hypersensitivity,Immune_system_disorders,NCT00001213,https://clinicaltrials.gov/show/NCT00001213,Cystinosis,Cysteamine,2,328,other_events,arm0,Cysteamine Topical Solution,2,328
Drug_hypersensitivity,Immune_system_disorders,NCT00027027,https://clinicaltrials.gov/show/NCT00027027,Neoplasms,rhuMAb_2C4,1,8,serious_events,arm4,rhuMAb 2C4: 15 mg/kg,1,8
Drug_hypersensitivity,Immune_system_disorders,NCT00040664,https://clinicaltrials.gov/show/NCT00040664,HIV_Infection,ritonavir|fosamprenavir|,3,69,serious_events,arm0,FPV/RTV,3,69
Drug_hypersensitivity,Immune_system_disorders,NCT00050011,https://clinicaltrials.gov/show/NCT00050011,Breast_Neoplasms|Osteoporosis|,Zoledronic_Acid|Letrozole|,1,300,serious_events,arm1,Zoledronic Acid Delayed-start,1,300
Drug_hypersensitivity,Immune_system_disorders,NCT00054717,https://clinicaltrials.gov/show/NCT00054717,HIV_Infections,Tipranavir|Ritonavir(r)|Comparator_Protease_Inhibitor_(CPI)|,1,309,serious_events,arm1,Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r),1,309
Drug_hypersensitivity,Immune_system_disorders,NCT00054847,https://clinicaltrials.gov/show/NCT00054847,Cardiovascular_Disease|Coronary_Artery_Disease|,saphenous_vein_graft|radial_artery_graft|,2,733,other_events,arm0,Arm 1,1,367
Drug_hypersensitivity,Immune_system_disorders,NCT00054847,https://clinicaltrials.gov/show/NCT00054847,Cardiovascular_Disease|Coronary_Artery_Disease|,saphenous_vein_graft|radial_artery_graft|,2,733,other_events,arm1,Arm 2,1,366
Drug_Hypersensitivity,Immune_system_disorders,NCT00056563,https://clinicaltrials.gov/show/NCT00056563,Parkinson's_Disease,Bilateral_Deep_Brain_Stimulation|best_medical_therapy|,1,121,serious_events,arm0,1: Bilateral Deep Brain Stimulation,1,121
Drug_hypersensitivity,Immune_system_disorders,NCT00057330,https://clinicaltrials.gov/show/NCT00057330,Herpes_Simplex_Infection,HSV_vaccine_or_SB208141_GSK_Biologicals'_glycoprotein_D_(gD)-Alum/3-deacylated_form_of_Monophosphoryl_Lipid_A_(MPL)_candidate_genital_herpes_vaccine|Havrix_ ¢_GlaxoSmithKline_(GSK)_Biologicals'_licensed_Hepatitis_A_vaccine|,3,8150,serious_events,arm0,Herpes Simplex Virus Group,2,4488
Drug_hypersensitivity,Immune_system_disorders,NCT00057330,https://clinicaltrials.gov/show/NCT00057330,Herpes_Simplex_Infection,HSV_vaccine_or_SB208141_GSK_Biologicals'_glycoprotein_D_(gD)-Alum/3-deacylated_form_of_Monophosphoryl_Lipid_A_(MPL)_candidate_genital_herpes_vaccine|Havrix_ ¢_GlaxoSmithKline_(GSK)_Biologicals'_licensed_Hepatitis_A_vaccine|,3,8150,serious_events,arm1,Havrix Group,1,3662
Drug_hypersensitivity,Immune_system_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,1,102,serious_events,arm1,Best Supportive Care Only,1,102
Drug_hypersensitivity,Immune_system_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,4,579,other_events,arm0,Lapatinib With Paclitaxel,3,293
Drug_hypersensitivity,Immune_system_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,4,579,other_events,arm1,Placebo With Paclitaxel,1,286
Drug_hypersensitivity,Immune_system_disorders,NCT00079781,https://clinicaltrials.gov/show/NCT00079781,Epilepsy,RNS‘Œ_System_implantation|RNS‘Œ_System_responsive_stimulation|,4,65,other_events,arm1,Sham Group,1,14
Drug_hypersensitivity,Immune_system_disorders,NCT00079781,https://clinicaltrials.gov/show/NCT00079781,Epilepsy,RNS‘Œ_System_implantation|RNS‘Œ_System_responsive_stimulation|,4,65,other_events,arm0,Treatment Population,3,51
Drug_hypersensitivity,Immune_system_disorders,NCT00079937,https://clinicaltrials.gov/show/NCT00079937,Asthma,Omalizumab|Placebo|Fluticasone|,1,421,serious_events,arm0,Omalizumab,1,421
Drug_Hypersensitivity,Immune_system_disorders,NCT00084084,https://clinicaltrials.gov/show/NCT00084084,Fabry_Disease,Agalsidase_alfa,2,28,other_events,arm1,Transition Safety Population,1,11
Drug_Hypersensitivity,Immune_system_disorders,NCT00084084,https://clinicaltrials.gov/show/NCT00084084,Fabry_Disease,Agalsidase_alfa,2,28,other_events,arm0,Safety Population RB,1,17
Drug_hypersensitivity,Immune_system_disorders,NCT00084136,https://clinicaltrials.gov/show/NCT00084136,HIV_Infections,Atazanavir|Didanosine_(enteric-coated)|Efavirenz|Emtricitabine|Emtricitabine/Tenofovir_disoproxil_fumarate|Lamivudine/Zidovudine|,3,1045,serious_events,arm0,ZDV/3TC+EFV,1,519
Drug_hypersensitivity,Immune_system_disorders,NCT00084136,https://clinicaltrials.gov/show/NCT00084136,HIV_Infections,Atazanavir|Didanosine_(enteric-coated)|Efavirenz|Emtricitabine|Emtricitabine/Tenofovir_disoproxil_fumarate|Lamivudine/Zidovudine|,3,1045,serious_events,arm1,ddI+FTC+ATV,2,526
Drug_hypersensitivity,Immune_system_disorders,NCT00084266,https://clinicaltrials.gov/show/NCT00084266,Methicillin_Resistant_Staphylococcus_Aureus_(MRSA),linezolid_(Zyvox)|vancomycin|,1,587,other_events,arm1,Vancomycin,1,587
Drug_hypersensitivity,Immune_system_disorders,NCT00085644,https://clinicaltrials.gov/show/NCT00085644,Ankylosing_Spondylitis,adalimumab_(D2E7)|placebo|,1,311,serious_events,arm0,Any Adalimumab,1,311
Drug_hypersensitivity,Immune_system_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,1,164,other_events,arm0,Combination Arm (FluCAM),1,164
Drug_hypersensitivity,Immune_system_disorders,NCT00087490,https://clinicaltrials.gov/show/NCT00087490,Skin/Soft_Tissue_Infections|Methicillin_Resistant_Staphylococcus_Aureus_(MRSA)|,linezolid|vancomycin|,2,1052,other_events,arm0,Linezolid,1,537
Drug_hypersensitivity,Immune_system_disorders,NCT00087490,https://clinicaltrials.gov/show/NCT00087490,Skin/Soft_Tissue_Infections|Methicillin_Resistant_Staphylococcus_Aureus_(MRSA)|,linezolid|vancomycin|,2,1052,other_events,arm1,Vancomycin,1,515
Drug_hypersensitivity,Immune_system_disorders,NCT00087698,https://clinicaltrials.gov/show/NCT00087698,Pleural_Neoplasms,pemetrexed|cisplatin|,6,77,other_events,arm0,Pemetrexed,6,77
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00089479,https://clinicaltrials.gov/show/NCT00089479,Breast_Cancer,capecitabine_[Xeloda]|Taxotere|Taxotere|,1,1283,serious_events,arm1,AC Then XT,1,1283
Drug_hypersensitivity,Immune_system_disorders,NCT00089674,https://clinicaltrials.gov/show/NCT00089674,Prostate_Cancer,AMG_162|Placebo|,1,731,serious_events,arm1,Denosumab 60 mg Q6M,1,731
Drug_hypersensitivity,Immune_system_disorders,NCT00089583,https://clinicaltrials.gov/show/NCT00089583,Infection_Human_Immunodeficiency_Virus_I,LEXIVA_(GW433908)|Ritonavir|,9,109,serious_events,arm1,FPV/RTV Treatment Group,6,89
Drug_hypersensitivity,Immune_system_disorders,NCT00089583,https://clinicaltrials.gov/show/NCT00089583,Infection_Human_Immunodeficiency_Virus_I,LEXIVA_(GW433908)|Ritonavir|,9,109,serious_events,arm0,FPV Treatment Group,3,20
Drug_hypersensitivity,Immune_system_disorders,NCT00089791,https://clinicaltrials.gov/show/NCT00089791,Osteoporosis,placebo|Denosumab|,1,3886,serious_events,arm1,Denosumab 60 mg Q6M,1,3886
Drug_Hypersensitivity,Immune_system_disorders,NCT00090051,https://clinicaltrials.gov/show/NCT00090051,Chronic_Lymphocytic_Leukemia,Rituximab|Fludarabine_Phosphate|Cyclophosphamide|,1,274,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab (FCR),1,274
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00090753,https://clinicaltrials.gov/show/NCT00090753,Anemia,Methoxy_Polyethylene_Glycol-Epoetin_Beta|Epoetin_alfa|Epoetin_beta|Darbepoetin_alfa|,1,748,serious_events,arm0,Methoxy Polyethylene Glycol-Epoetin Beta,1,748
Drug_Hypersensitivity,Immune_system_disorders,NCT00091819,https://clinicaltrials.gov/show/NCT00091819,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,2,855,serious_events,arm1,Vancomycin,1,429
Drug_Hypersensitivity,Immune_system_disorders,NCT00091819,https://clinicaltrials.gov/show/NCT00091819,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,2,855,serious_events,arm0,Telavancin,1,426
Drug_hypersensitivity,Immune_system_disorders,NCT00093145,https://clinicaltrials.gov/show/NCT00093145,Breast_Cancer,Albumin-bound_paclitaxel|Carboplatin|Herceptin‘Œ|,4,32,other_events,arm0,Albumin-bound Paclitaxel Carboplatin + Herceptin,4,32
Drug_hypersensitivity,Immune_system_disorders,NCT00093015,https://clinicaltrials.gov/show/NCT00093015,Kidney_Disease|Diabetes_Mellitus|Anemia|,Placebo|darbepoetin_alfa|,1,2019,serious_events,arm0,Placebo,1,2019
Drug_hypersensitivity,Immune_system_disorders,NCT00094107,https://clinicaltrials.gov/show/NCT00094107,Melanoma|Skin_Neoplasms|,Axitinib_[AG-013736],1,32,other_events,arm0,Axitinib,1,32
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00095238,https://clinicaltrials.gov/show/NCT00095238,Congestive_Heart_Failure,Irbesartan|Placebo|,1,2064,serious_events,arm0,IRBESARTAN,1,2064
Drug_hypersensitivity,Immune_system_disorders,NCT00095576,https://clinicaltrials.gov/show/NCT00095576,AIDS|HIV_Infections|,Trivalent_MRKAd5_HIV-1_gag/pol/nef_(1.5x10^10_ad-vg/dose)|Comparator:_placebo|,1,1495,serious_events,arm1,Placebo,1,1495
Drug_Hypersensitivity,Immune_system_disorders,NCT00097773,https://clinicaltrials.gov/show/NCT00097773,Cystic_Fibrosis|Pulmonary_Disease_Chronic_Obstructive|,Tobramycin_solution_for_inhalation_(TOBI)|Oral_placebo|Oral_ciprofloxacin|,1,76,serious_events,arm1,Cycled TIS w/Cipro,1,76
Drug_hypersensitivity,Immune_system_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,4,13457,serious_events,arm1,Clopidogrel,3,6716
Drug_hypersensitivity,Immune_system_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,4,13457,serious_events,arm0,Prasugrel,1,6741
Drug_hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,10,9201,serious_events,arm2,Nateglinide 60 mg ac + Placebo Valsartan,3,2305
Drug_hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,10,9201,serious_events,arm0,Valsartan 160 mg od + Nateglinide 60 mg ac,3,2297
Drug_hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,10,9201,serious_events,arm3,Placebo,3,2316
Drug_hypersensitivity,Immune_system_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,10,9201,serious_events,arm1,Valsartan 160 mg od + Placebo Nateglinide,1,2283
Drug_hypersensitivity,Immune_system_disorders,NCT00098293,https://clinicaltrials.gov/show/NCT00098293,HIV-1,Maraviroc_+_Zidovudine/Lamivudine|Efavirenz_+_Zidovudine/Lamivudine|Maraviroc_(UK-427857)_+_Zidovudine/Lamivudine|,1,360,serious_events,arm1,Maraviroc Twice Daily + CBV (DB and OL),1,360
Drug_hypersensitivity,Immune_system_disorders,NCT00098306,https://clinicaltrials.gov/show/NCT00098306,HIV_Infections,Maraviroc_(UK-427857)|Optimized_Background_Therapy|Optimized_Background_Therapy|Placebo|Optimized_Background_Therapy|,1,235,serious_events,arm1,Maraviroc BID Double Blind,1,235
Drug_hypersensitivity,Immune_system_disorders,NCT00098722,https://clinicaltrials.gov/show/NCT00098722,HIV_Infections,Maraviroc_(UK-427857)|optimized_background_therapy|Maraviroc_(UK-427857)|optimized_background_therapy|optimized_background_therapy|,3,464,serious_events,arm0,Maraviroc QD,1,182
Drug_hypersensitivity,Immune_system_disorders,NCT00098722,https://clinicaltrials.gov/show/NCT00098722,HIV_Infections,Maraviroc_(UK-427857)|optimized_background_therapy|Maraviroc_(UK-427857)|optimized_background_therapy|optimized_background_therapy|,3,464,serious_events,arm1,Maraviroc BID,1,191
Drug_hypersensitivity,Immune_system_disorders,NCT00098722,https://clinicaltrials.gov/show/NCT00098722,HIV_Infections,Maraviroc_(UK-427857)|optimized_background_therapy|Maraviroc_(UK-427857)|optimized_background_therapy|optimized_background_therapy|,3,464,serious_events,arm2,Placebo,1,91
Drug_hypersensitivity,Immune_system_disorders,NCT00101686,https://clinicaltrials.gov/show/NCT00101686,Colorectal_Neoplasms,Modified_Bolus_5-FU/LV_with_Irinotecan|FOLFIRI_+_bevacizumab|miFL_+_bevacizumab|Infusional_5-FU/LV_with_Irinotecan|Oral_Capecitabine_with_Irinotecan|,1,137,serious_events,arm0,FOLFIRI,1,137
Drug_hypersensitivity,Immune_system_disorders,NCT00104299,https://clinicaltrials.gov/show/NCT00104299,Vasculitis|Wegener's_Granulomatosis|Microscopic_Polyangiitis|,Rituximab_plus_cyclophosphamide_placebo_(rituximab_group)|Cyclophosphamide_plus_rituximab_placebo_(control_group)|Azathioprine|Methylprednisolone_(or_other_glucocorticoid)|Prednisone|,2,98,serious_events,arm1,Control Group,2,98
Drug_hypersensitivity,Immune_system_disorders,NCT00105027,https://clinicaltrials.gov/show/NCT00105027,Macular_Edema_Cystoid|Retinal_Vein_Occlusion|,Standard_Care|intravitreal_triamcinolone_injection|intravitreal_triamcinolone_injection|,1,136,serious_events,arm4,BRVO 1 mg Dose Triamcinolone Acetonide,1,136
Drug_Hypersensitivity,Immune_system_disorders,NCT00105157,https://clinicaltrials.gov/show/NCT00105157,HIV_Infections|Acquired_Immunodeficiency_Syndrome|,Comparator:_MK0518|MK0518|MK0518|Placebo|,2,178,other_events,arm0,MK0518,1,133
Drug_Hypersensitivity,Immune_system_disorders,NCT00105157,https://clinicaltrials.gov/show/NCT00105157,HIV_Infections|Acquired_Immunodeficiency_Syndrome|,Comparator:_MK0518|MK0518|MK0518|Placebo|,2,178,other_events,arm1,Placebo,1,45
Drug_hypersensitivity,Immune_system_disorders,NCT00106535,https://clinicaltrials.gov/show/NCT00106535,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|Placebo|Methotrexate|,1,1054,serious_events,arm2,All Tocilizumab 8 mg/kg + Methotrexate,1,1054
Drug_Hypersensitivity,Immune_system_disorders,NCT00107978,https://clinicaltrials.gov/show/NCT00107978,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,14,2024,serious_events,arm1,Vancomycin,1,509
Drug_Hypersensitivity,Immune_system_disorders,NCT00107978,https://clinicaltrials.gov/show/NCT00107978,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,14,2024,other_events,arm1,Vancomycin,6,509
Drug_Hypersensitivity,Immune_system_disorders,NCT00107978,https://clinicaltrials.gov/show/NCT00107978,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,14,2024,serious_events,arm0,Telavancin,2,503
Drug_Hypersensitivity,Immune_system_disorders,NCT00107978,https://clinicaltrials.gov/show/NCT00107978,Staphylococcal_Skin_Infection,Telavancin|Vancomycin|,14,2024,other_events,arm0,Telavancin,5,503
Drug_hypersensitivity,Immune_system_disorders,NCT00108082,https://clinicaltrials.gov/show/NCT00108082,Hypertension|Left_Ventricular_Hypertrophy|,carvedilol_MR|atenolol|lisinopril|,1,100,serious_events,arm1,Atenolol,1,100
Drug_hypersensitivity,Immune_system_disorders,NCT00112294,https://clinicaltrials.gov/show/NCT00112294,Non-Small-Cell_Lung_Carcinoma,Paclitaxel_(Taxane)|Docetaxel_(Taxane)|Carboplatin|Cetuximab|,1,320,serious_events,arm1,Taxane+Carboplatin,1,320
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,serious_events,arm0,FOLFOX4,5,1126
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,serious_events,arm1,FOLFOX4 + Bv,3,1145
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,other_events,arm0,FOLFOX4,66,1126
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,other_events,arm1,FOLFOX4 + Bv,72,1145
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,serious_events,arm2,XELOX+Bv,1,1135
Drug_hypersensitivity,Immune_system_disorders,NCT00112918,https://clinicaltrials.gov/show/NCT00112918,Colorectal_Cancer,Bevacizumab|Capecitabine|5-Fluorouracil_(5-FU)|Leucovorin_calcium|Oxaliplatin|,179,6812,other_events,arm2,XELOX+Bv,32,1135
Drug_Hypersensitivity,Immune_system_disorders,NCT00112437,https://clinicaltrials.gov/show/NCT00112437,Osteoporosis,MK0822|MK0822|MK0822|MK0822|Vitamin_D3|Calcium_Carbonate|Placebo|,2,41,other_events,arm14,MK0822 50 mg / MK0822 50 mg,1,20
Drug_Hypersensitivity,Immune_system_disorders,NCT00112437,https://clinicaltrials.gov/show/NCT00112437,Osteoporosis,MK0822|MK0822|MK0822|MK0822|Vitamin_D3|Calcium_Carbonate|Placebo|,2,41,other_events,arm12,MK0822 25 mg / MK0822 50 mg,1,21
Drug_Hypersensitivity,Immune_system_disorders,NCT00113607,https://clinicaltrials.gov/show/NCT00113607,Ovarian_Cancer,Trabectedin|DOXIL|Dexamethasone|,1,330,serious_events,arm1,DOXIL,1,330
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,3,1028,serious_events,arm0,Panit. Plus Bevacizumab With Chemotherapy,2,518
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00115765,https://clinicaltrials.gov/show/NCT00115765,Colorectal_Cancer,Oxaliplatin_Based_Chemotherapy|Panitumumab|Irinotecan_Based_Chemotherapy|Bevacizumab|,3,1028,serious_events,arm1,Bevacizumab With Chemotherapy,1,510
Drug_Hypersensitivity,Immune_system_disorders,NCT00118755,https://clinicaltrials.gov/show/NCT00118755,Colorectal_Cancer,capecitabine|Oxaliplatin|bevacizumab|capecitabine|Oxaliplatin|bevacizumab|,1,211,serious_events,arm1,XELOX Q2W + Bevacizumab,1,211
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,other_events,arm1,EFV Placebo FTC/TDF and ABC/3TC,49,461
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,other_events,arm2,RTV-boosted ATV FTC/TDF and Placebo ABC/3TC,29,464
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,serious_events,arm3,RTV-boosted ATV Placebo FTC/TDF and ABC/3TC,7,462
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,other_events,arm3,RTV-boosted ATV Placebo FTC/TDF and ABC/3TC,30,462
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,serious_events,arm1,EFV Placebo FTC/TDF and ABC/3TC,5,461
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,serious_events,arm2,RTV-boosted ATV FTC/TDF and Placebo ABC/3TC,2,464
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,serious_events,arm0,EFV FTC/TDF and Placebo ABC/3TC,1,461
Drug_hypersensitivity,Immune_system_disorders,NCT00118898,https://clinicaltrials.gov/show/NCT00118898,HIV_Infections,Abacavir/Lamivudine|Atazanavir|Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|Ritonavir|Abacavir/Lamivudine_placebo|Emtricitabine/Tenofovir_disoproxil_fumarate_placebo|,145,3696,other_events,arm0,EFV FTC/TDF and Placebo ABC/3TC,22,461
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00119678,https://clinicaltrials.gov/show/NCT00119678,Systemic_Lupus_Erythematosus,Abatacept|Placebo|Prednisone|Abatacept|,1,121,serious_events,arm0,Abatacept,1,121
Drug_hypersensitivity,Immune_system_disorders,NCT00120523,https://clinicaltrials.gov/show/NCT00120523,Atopic_Dermatitis,Pimecrolimus|Topical_corticosteroids|,1,1205,serious_events,arm0,Pimecrolimus,1,1205
Drug_Hypersensitivity,Immune_system_disorders,NCT00121810,https://clinicaltrials.gov/show/NCT00121810,Kidney_Transplantation,mycophenolate_mofetil_[CellCept]|Corticosteroids|Calcineurin_inhibitors|Sirolimus|,2,301,serious_events,arm1,Mycophenolate Mofetil + Cyclosporine or Tacrolimus,1,153
Drug_Hypersensitivity,Immune_system_disorders,NCT00121810,https://clinicaltrials.gov/show/NCT00121810,Kidney_Transplantation,mycophenolate_mofetil_[CellCept]|Corticosteroids|Calcineurin_inhibitors|Sirolimus|,2,301,serious_events,arm0,Mycophenolate Mofetil + Sirolimus,1,148
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00121667,https://clinicaltrials.gov/show/NCT00121667,Diabetes_Mellitus_Type_2,Saxagliptin_+_Metformin|Saxagliptin_+_Metformin|Saxagliptin_+_Metformin|Placebo_+_Metformin|Pioglitazone|,1,192,serious_events,arm2,Saxagliptin 2.5 mg + Metformin,1,192
Drug_hypersensitivity,Immune_system_disorders,NCT00123487,https://clinicaltrials.gov/show/NCT00123487,Myeloid_Leukemia_Chronic_Accelerated_Phase|Leukemia_Lymphoblastic_Acute_Philadelphia-Positive|,dasatinib|dasatinib|,1,305,serious_events,arm1,Dasatinib 70 mg BID,1,305
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00129766,https://clinicaltrials.gov/show/NCT00129766,Respiratory_Syncytial_Virus_Infections,motavizumab_(MEDI-524)|palivizumab|,1,3315,serious_events,arm1,Motavizumab,1,3315
Drug_Hypersensitivity,Immune_system_disorders,NCT00137969,https://clinicaltrials.gov/show/NCT00137969,Lupus_Erythematosus_Systemic,Rituximab|Placebo|Prednisone|Acetaminophen|Diphenhydramine|,1,169,serious_events,arm0,Rituximab 1000 mg + Prednisone,1,169
Drug_hypersensitivity,Immune_system_disorders,NCT00143247,https://clinicaltrials.gov/show/NCT00143247,Diabetes_Mellitus,Exubera‘Œ_(inhaled_insulin),1,173,other_events,arm0,Inhaled Insulin,1,173
Drug_hypersensitivity,Immune_system_disorders,NCT00144170,https://clinicaltrials.gov/show/NCT00144170,HIV_Infections,Tipranavir_(with_low_dose_ritonavir)|Comparator_protease_inhibitor(CPI)/low_dose_ritonavir(r)|,1,428,serious_events,arm1,Comparitor Protease Inhibitor(CPI)/Low Dose Ritonavir(r),1,428
drug_hypersensitivity,General_disorders,NCT00145041,https://clinicaltrials.gov/show/NCT00145041,Malignant_Melanoma,Vincristine_Sulfate_Liposomes_Injection,1,7,other_events,arm0,Overall Study,1,7
Drug_hypersensitivity,Immune_system_disorders,NCT00146328,https://clinicaltrials.gov/show/NCT00146328,HIV_Infections,Tipranavir,2,449,serious_events,arm2,Group 3 (Tipranavir naÍève Patients),2,449
Drug_hypersensitivity,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,3,180,other_events,arm6,CP-751871 10 mg/kg + Paclitaxel + Carboplatin (Phase 1b),1,17
Drug_hypersensitivity,Immune_system_disorders,NCT00147537,https://clinicaltrials.gov/show/NCT00147537,Carcinoma_Non-Small-Cell_Lung,CP-751871|paclitaxel|carboplatin|CP-751871|paclitaxel|carboplatin|erlotinib|,3,180,other_events,arm9,CP-751871 + Paclitaxel + Carboplatin (Phase 2),2,163
Drug_hypersensitivity,Immune_system_disorders,NCT00148798,https://clinicaltrials.gov/show/NCT00148798,Non_Small_Cell_Lung_Cancer_(NSCLC),cetuximab_+_cisplatin_+_vinorelbine|cisplatin_+_vinorelbine|,1,548,serious_events,arm0,Cetuximab Plus Chemotherapy,1,548
Drug_hypersensitivity,Immune_system_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,3,10023,serious_events,arm2,Clopidogrel / Telmisartan,1,5000
Drug_hypersensitivity,Immune_system_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,3,10023,serious_events,arm3,Clopidogrel / Placebo,2,5023
Drug_hypersensitivity,Immune_system_disorders,NCT00157248,https://clinicaltrials.gov/show/NCT00157248,Atrial_Fibrillation|Stroke|,dabigatran_etexilate|dabigatran_etexilate|dabigatran_etexilate|dabigatran_etexilate|,1,356,serious_events,arm3,150 mg Twice Daily,1,356
Drug_hypersensitivity,Immune_system_disorders,NCT00159861,https://clinicaltrials.gov/show/NCT00159861,Pulmonary_Hypertension,Sildenafil_citrate,4,364,other_events,arm0,Placebo/Sildenafil,2,115
Drug_hypersensitivity,Immune_system_disorders,NCT00159861,https://clinicaltrials.gov/show/NCT00159861,Pulmonary_Hypertension,Sildenafil_citrate,4,364,serious_events,arm0,Placebo/Sildenafil,1,115
Drug_hypersensitivity,Immune_system_disorders,NCT00159861,https://clinicaltrials.gov/show/NCT00159861,Pulmonary_Hypertension,Sildenafil_citrate,4,364,other_events,arm1,Sildenafil/Sildenafil,1,134
Drug_hypersensitivity,Immune_system_disorders,NCT00160693,https://clinicaltrials.gov/show/NCT00160693,Rheumatoid_Arthritis,Certolizumab_Pegol,1,402,serious_events,arm0,Certolizumab Pegol,1,402
Drug_hypersensitivity,Immune_system_disorders,NCT00168818,https://clinicaltrials.gov/show/NCT00168818,Thromboembolism|Arthroplasty_Replacement_Hip|,dabigatran_etexilate|dabigatran_etexilate|enoxaparin|,1,1146,serious_events,arm0,Dabigatran 220mg,1,1146
Drug_hypersensitivity,Immune_system_disorders,NCT00168844,https://clinicaltrials.gov/show/NCT00168844,Pulmonary_Disease_Chronic_Obstructive,Tiotropium_Inhalation_Solution|Placebo|,1,319,serious_events,arm2,Placebo,1,319
Drug_hypersensitivity,Immune_system_disorders,NCT00170950,https://clinicaltrials.gov/show/NCT00170950,Hypertension,Benazepril/amlodipine_20/5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/amlodipine_40/5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/amlodipine_40/10_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|Benazepril/hydrochlorothiazide_20/12.5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/hydrochlorothiazide_40/12.5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/hydrochlorothiazide_40/25_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|,4,11497,serious_events,arm1,Benazepril / HCTZ,2,5757
Drug_hypersensitivity,Immune_system_disorders,NCT00170950,https://clinicaltrials.gov/show/NCT00170950,Hypertension,Benazepril/amlodipine_20/5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/amlodipine_40/5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/amlodipine_40/10_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|Benazepril/hydrochlorothiazide_20/12.5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/hydrochlorothiazide_40/12.5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/hydrochlorothiazide_40/25_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|,4,11497,serious_events,arm0,Benazepril / Amlodipine,2,5740
Drug_hypersensitivity,Immune_system_disorders,NCT00174291,https://clinicaltrials.gov/show/NCT00174291,Endocrine_System_Diseases,Somatropin,1,11,serious_events,arm0,Somatropin (With Previous Somatropin Exposure),1,11
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00179647,https://clinicaltrials.gov/show/NCT00179647,Multiple_Myeloma,lenalidomide|dexamethasone|,1,1913,serious_events,arm0,Lenalidomide,1,1913
Drug_hypersensitivity,Immune_system_disorders,NCT00191139,https://clinicaltrials.gov/show/NCT00191139,Non-small_Cell_Lung_Cancer,gemcitabine|docetaxel|cisplatin|etoposide|radiation_therapy|,5,64,other_events,arm0,Gemcitabine,3,32
Drug_hypersensitivity,Immune_system_disorders,NCT00191139,https://clinicaltrials.gov/show/NCT00191139,Non-small_Cell_Lung_Cancer,gemcitabine|docetaxel|cisplatin|etoposide|radiation_therapy|,5,64,other_events,arm1,Gemcitabine Plus Docetaxel,2,32
Drug_hypersensitivity,Immune_system_disorders,NCT00191724,https://clinicaltrials.gov/show/NCT00191724,Submassive_Pulmonary_Embolism,Drotrecogin_Alfa_(Activated)|Enoxaparin|Placebo|Drotrecogin_Alfa_(Activated)|Drotrecogin_Alfa_(Activated)|Drotrecogin_Alfa_(Activated)|,1,9,other_events,arm2,Drotrecogin Alfa (Activated) - 18,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,3,820,serious_events,arm1,Paclitaxel/Carboplatin Induction,2,408
Drug_hypersensitivity,Immune_system_disorders,NCT00191646,https://clinicaltrials.gov/show/NCT00191646,Genital_Neoplasms_Female|Fallopian_Tube_Neoplasms|Ovarian_Neoplasms|Pelvic_Neoplasms|Peritoneal_Neoplasms|,Gemcitabine|Paclitaxel|Carboplatin|,3,820,serious_events,arm0,Gemcitabine/Carboplatin Induction,1,412
Drug_hypersensitivity,Immune_system_disorders,NCT00195442,https://clinicaltrials.gov/show/NCT00195442,Hemophilia_A,Moroctocog_alfa,1,288,other_events,arm0,ReFacto (Moroctocog Alfa),1,288
Drug_Hypersensitivity,Immune_system_disorders,NCT00195663,https://clinicaltrials.gov/show/NCT00195663,Early_Rheumatoid_Arthritis,Adalimumab|Methotrexate|Adalimumab_placebo|Methotrexate_placebo|,1,697,serious_events,arm3,Any Adalimumab,1,697
Drug_hypersensitivity,Immune_system_disorders,NCT00203047,https://clinicaltrials.gov/show/NCT00203047,Relapsing_Remitting_Multiple_Sclerosis,Glatiramer_Acetate|Placebo|Prednisone|,4,408,other_events,arm0,GA + Placebo,1,199
Drug_hypersensitivity,Immune_system_disorders,NCT00203047,https://clinicaltrials.gov/show/NCT00203047,Relapsing_Remitting_Multiple_Sclerosis,Glatiramer_Acetate|Placebo|Prednisone|,4,408,other_events,arm1,GA + Prednisone,3,209
Drug_Hypersensitivity,Immune_system_disorders,NCT00202878,https://clinicaltrials.gov/show/NCT00202878,Hypercholesterolemia|Myocardial_Infarction|,ezetimibe/simvastatin|simvastatin|Placebo_for_simvastatin_40_mg|Placebo_for_ezetimibe_10_mg/simvastatin_40_mg_combination|,4,18144,serious_events,arm0,Ezetimide/Simvastatin,2,9067
Drug_Hypersensitivity,Immune_system_disorders,NCT00202878,https://clinicaltrials.gov/show/NCT00202878,Hypercholesterolemia|Myocardial_Infarction|,ezetimibe/simvastatin|simvastatin|Placebo_for_simvastatin_40_mg|Placebo_for_ezetimibe_10_mg/simvastatin_40_mg_combination|,4,18144,serious_events,arm1,Simvastatin,2,9077
Drug_hypersensitivity,Immune_system_disorders,NCT00205803,https://clinicaltrials.gov/show/NCT00205803,Healthy_Subjects|Pneumococcal_Infections|,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnC)|,2,223,other_events,arm5,7vPnC 6-Month Follow-up,1,103
Drug_hypersensitivity,Immune_system_disorders,NCT00205803,https://clinicaltrials.gov/show/NCT00205803,Healthy_Subjects|Pneumococcal_Infections|,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnC)|,2,223,other_events,arm0,13vPnC Infant Series,1,120
Drug_hypersensitivity,Immune_system_disorders,NCT00230178,https://clinicaltrials.gov/show/NCT00230178,Tumor_Lysis_Syndrome|Cancer|Hyperuricemia|,Rasburicase_(SR29142)|Allopurinol|,1,92,serious_events,arm1,Rasburicase + Allopurinol,1,92
Drug_hypersensitivity,Immune_system_disorders,NCT00232180,https://clinicaltrials.gov/show/NCT00232180,Heart_Failure,Eplerenone,2,2741,serious_events,arm3,Placebo: Double-blind Phase,1,1372
Drug_hypersensitivity,Immune_system_disorders,NCT00232180,https://clinicaltrials.gov/show/NCT00232180,Heart_Failure,Eplerenone,2,2741,serious_events,arm1,Placebo: Double-blind Phase(May 25 2010 Data Cutoff),1,1369
Drug_hypersensitivity,Immune_system_disorders,NCT00234884,https://clinicaltrials.gov/show/NCT00234884,Rheumatoid_Arthritis,adalimumab,1,3435,serious_events,arm0,Adalimumab,1,3435
Drug_hypersensitivity,Immune_system_disorders,NCT00239681,https://clinicaltrials.gov/show/NCT00239681,Elevated_High-sensitivity_C-Reactive_Protein_(hsCRP),Rosuvastatin|Placebo|,4,8869,serious_events,arm1,ROSUVASTATIN 20 MG,4,8869
Drug_hypersensitivity,Immune_system_disorders,NCT00244712,https://clinicaltrials.gov/show/NCT00244712,HIV_Infection,emtricitabine/tenofovir|abacavir/lamivudine|,15,688,serious_events,arm1,Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV,3,345
Drug_hypersensitivity,Immune_system_disorders,NCT00244712,https://clinicaltrials.gov/show/NCT00244712,HIV_Infection,emtricitabine/tenofovir|abacavir/lamivudine|,15,688,serious_events,arm0,Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV),12,343
Drug_Hypersensitivity,Immune_system_disorders,NCT00247273,https://clinicaltrials.gov/show/NCT00247273,Postmenopausal_Osteoporosis,risedronate|risedronate|,1,642,serious_events,arm0,5 mg Risedronate,1,642
Drug_hypersensitivity,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,3,4111,serious_events,arm0,Letrozole,2,2049
Drug_hypersensitivity,Immune_system_disorders,NCT00248170,https://clinicaltrials.gov/show/NCT00248170,Breast_Cancer,Letrozole|Anastrozole|,3,4111,serious_events,arm1,Anastrozole,1,2062
Drug_hypersensitivity,Immune_system_disorders,NCT00249795,https://clinicaltrials.gov/show/NCT00249795,Atrial_Fibrillation|Cardiovascular_Disease|,Irbesartan|placebo|,2,9016,serious_events,arm1,Placebo,1,4498
Drug_hypersensitivity,Immune_system_disorders,NCT00249795,https://clinicaltrials.gov/show/NCT00249795,Atrial_Fibrillation|Cardiovascular_Disease|,Irbesartan|placebo|,2,9016,serious_events,arm0,Irbesartan,1,4518
Drug_hypersensitivity,Immune_system_disorders,NCT00249873,https://clinicaltrials.gov/show/NCT00249873,Atrial_Fibrillation|Vascular_Risk|,clopidogrel_(SR25990C)|placebo|,1,3772,serious_events,arm0,Clopidogrel + ASA,1,3772
Drug_Hypersensitivity,Immune_system_disorders,NCT00256204,https://clinicaltrials.gov/show/NCT00256204,Parkinson's_Disease,Rasagiline_Mesylate|Rasagiline_Mesylate|Placebo|,1,288,serious_events,arm1,1mg Active Treatment,1,288
Drug_Hypersensitivity,Immune_system_disorders,NCT00257010,https://clinicaltrials.gov/show/NCT00257010,Migraine,Almotriptan_Malate,1,420,other_events,arm0,Almotriptan Malate,1,420
Drug_hypersensitivity,Immune_system_disorders,NCT00260208,https://clinicaltrials.gov/show/NCT00260208,Liver_Transplant|Hepatitis_C|,Cyclosporine_A|Tacrolimus|,1,184,serious_events,arm0,Cyclosporin A,1,184
Drug_hypersensitivity,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,3,570,serious_events,arm1,CP3L-CML,1,118
Drug_hypersensitivity,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,3,570,serious_events,arm0,CP2L-CML,1,288
Drug_hypersensitivity,Immune_system_disorders,NCT00261846,https://clinicaltrials.gov/show/NCT00261846,Chronic_Myeloid_Leukemia,Bosutinib,3,570,serious_events,arm2,Advanced Phase,1,164
Drug_hypersensitivity,Immune_system_disorders,NCT00262600,https://clinicaltrials.gov/show/NCT00262600,Atrial_Fibrillation|Stroke|,warfarin|Dabigatran_dose_1|Dabigatran_dose_2|,2,12057,serious_events,arm1,Dabigatran 150 mg,1,6059
Drug_hypersensitivity,Immune_system_disorders,NCT00262600,https://clinicaltrials.gov/show/NCT00262600,Atrial_Fibrillation|Stroke|,warfarin|Dabigatran_dose_1|Dabigatran_dose_2|,2,12057,serious_events,arm2,Warfarin,1,5998
Drug_hypersensitivity,Immune_system_disorders,NCT00263887,https://clinicaltrials.gov/show/NCT00263887,Alpha_1-Antitrypsin_Deficiency,Alpha1-Proteinase_Inhibitor_(Human)|Albumin_(Human)_20_PERCENT_United_States_Pharmacopeia_(USP)|,2,38,other_events,arm0,Prolastin (60 mg/kg Body Weight),2,38
Drug_hypersensitivity,Immune_system_disorders,NCT00264810,https://clinicaltrials.gov/show/NCT00264810,Epilepsy,RNS‘Œ_System_implantation|RNS‘Œ_System_responsive_stimulation|,9,288,serious_events,arm0,Treatment Group (Stimulation ON),1,97
Drug_hypersensitivity,Immune_system_disorders,NCT00264810,https://clinicaltrials.gov/show/NCT00264810,Epilepsy,RNS‘Œ_System_implantation|RNS‘Œ_System_responsive_stimulation|,9,288,other_events,arm0,Treatment Group (Stimulation ON),4,97
Drug_hypersensitivity,Immune_system_disorders,NCT00264810,https://clinicaltrials.gov/show/NCT00264810,Epilepsy,RNS‘Œ_System_implantation|RNS‘Œ_System_responsive_stimulation|,9,288,other_events,arm1,Sham Group (Stimulation OFF),4,94
Drug_hypersensitivity,Immune_system_disorders,NCT00264849,https://clinicaltrials.gov/show/NCT00264849,Asthma,Omalizumab|Optimized_asthma_therapy|,1,128,serious_events,arm1,Optimized Asthma Treatment (OAT),1,128
Drug_Hypersensitivity,Immune_system_disorders,NCT00267007,https://clinicaltrials.gov/show/NCT00267007,Peripheral_Neuropathy_Chemotherapy-induced,PROCRIT_40000_IU_QW|Placebo|,1,19,other_events,arm0,PROCRIT 40000 IU QW,1,19
Drug_hypersensitivity,General_disorders,NCT00271154,https://clinicaltrials.gov/show/NCT00271154,Heart_Failure,Cardiac_Resynchronization_Therapy_(CRT)_Device_or_Implantable_Cardioverter_Defibrillator_(ICD)_with_CRT,2,610,serious_events,arm0,CRT OFF,1,191
Drug_hypersensitivity,General_disorders,NCT00271154,https://clinicaltrials.gov/show/NCT00271154,Heart_Failure,Cardiac_Resynchronization_Therapy_(CRT)_Device_or_Implantable_Cardioverter_Defibrillator_(ICD)_with_CRT,2,610,serious_events,arm1,CRT ON,1,419
Drug_hypersensitivity,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,3,34,other_events,arm2,Paclitaxel 80 mg/Trastuzumab 4 mg/Lapatinib 750 mg,2,20
Drug_hypersensitivity,Immune_system_disorders,NCT00272987,https://clinicaltrials.gov/show/NCT00272987,Neoplasms_Breast,lapatinib|paclitaxel|trastuzumab|,3,34,serious_events,arm1,Paclitaxel 70 mg/Trastuzumab 4 mg/Lapatinib 1000 mg,1,14
Drug_Hypersensitivity,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,13,348,serious_events,arm1,FOLFOX + Cediranib 30 mg,1,73
Drug_Hypersensitivity,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,13,348,other_events,arm0,FOLFOX + Cediranib 20 mg,4,70
Drug_Hypersensitivity,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,13,348,other_events,arm2,FOLFOX + Bevacizumab 10 mg/kg,5,66
Drug_Hypersensitivity,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,13,348,other_events,arm1,FOLFOX + Cediranib 30 mg,2,73
Drug_Hypersensitivity,Immune_system_disorders,NCT00278889,https://clinicaltrials.gov/show/NCT00278889,Colorectal_Cancer,AZD2171|5-fluorouracil|Leucovorin|Oxaliplatin|Bevacizumab|,13,348,serious_events,arm2,FOLFOX + Bevacizumab 10 mg/kg,1,66
Drug_Hypersensitivity,Immune_system_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,2,402,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab (FCR),2,402
Drug_hypersensitivity,Immune_system_disorders,NCT00283049,https://clinicaltrials.gov/show/NCT00283049,Diabetes_Mellitus_Type_2,Insulin_Glargine|Insulin_Glulisine|,1,130,serious_events,arm2,Insulin Glargine + Metformin (MET) + Sulfonylurea (SU),1,130
Drug_hypersensitivity,Immune_system_disorders,NCT00283062,https://clinicaltrials.gov/show/NCT00283062,Prostatic_Neoplasms,Docetaxel_(TAXOTERE‘Œ)_Chemotherapy|Leuprolide_acetate_(_ELIGARD‘Œ)_Hormonal_Therapy|Docetaxel_(TAXOTERE‘Œ)_Chemotherapy|Leuprolide_acetate_(_ELIGARD‘Œ)_Hormonal_Therapy|Leuprolide_acetate_(_ELIGARD‘Œ)_Hormonal_Therapy|,1,17,other_events,arm3,Leuprolide Acetate - Deferred Treatment (D-HT),1,17
Drug_hypersensitivity,Immune_system_disorders,NCT00293254,https://clinicaltrials.gov/show/NCT00293254,HIV_Infections,raltegravir_potassium|Comparator:_placebo|,1,119,serious_events,arm1,Placebo Plus OBT,1,119
Drug_hypersensitivity,Immune_system_disorders,NCT00293267,https://clinicaltrials.gov/show/NCT00293267,HIV_Infections,raltegravir_potassium|Comparator:_Placebo|,1,232,serious_events,arm0,Raltegravir 400 mg b.i.d Plus OBT,1,232
Drug_hypersensitivity,Immune_system_disorders,NCT00294047,https://clinicaltrials.gov/show/NCT00294047,Infections_Papillomavirus,Cervarix|Placebo_control|,3,5747,serious_events,arm0,Cervarix Group,1,2877
Drug_hypersensitivity,Immune_system_disorders,NCT00294047,https://clinicaltrials.gov/show/NCT00294047,Infections_Papillomavirus,Cervarix|Placebo_control|,3,5747,serious_events,arm1,Aluminium Hydroxide Group,2,2870
Drug_hypersensitivity,Immune_system_disorders,NCT00296504,https://clinicaltrials.gov/show/NCT00296504,Infection_Human_Immunodeficiency_Virus,fosamprenavir_(GW433908)|ritonavir|,28,413,serious_events,arm2,FPV Population (APV30002),16,221
Drug_hypersensitivity,Immune_system_disorders,NCT00296504,https://clinicaltrials.gov/show/NCT00296504,Infection_Human_Immunodeficiency_Virus,fosamprenavir_(GW433908)|ritonavir|,28,413,serious_events,arm4,FPV/RTV QD Population (APV30003),1,73
Drug_hypersensitivity,Immune_system_disorders,NCT00296504,https://clinicaltrials.gov/show/NCT00296504,Infection_Human_Immunodeficiency_Virus,fosamprenavir_(GW433908)|ritonavir|,28,413,serious_events,arm0,FPV Population (APV30001),11,119
Drug_hypersensitivity,Immune_system_disorders,NCT00297102,https://clinicaltrials.gov/show/NCT00297102,Chronic_Obstructive_Pulmonary_Disease_(COPD),Roflumilast|Placebo|,1,755,serious_events,arm1,Placebo,1,755
Drug_hypersensitivity,Immune_system_disorders,NCT00297232,https://clinicaltrials.gov/show/NCT00297232,Relapsing-Remitting_Multiple_Sclerosis,Natalizumab,1,1094,serious_events,arm0,Natalizumab,1,1094
Drug_hypersensitivity,Immune_system_disorders,NCT00299130,https://clinicaltrials.gov/show/NCT00299130,Rheumatoid_Arthritis,Folate|Methotrexate|Methylprednisolone|Placebo|Rituximab|,1,155,serious_events,arm4,Switch Population: Rituximab,1,155
Drug_hypersensitivity,Immune_system_disorders,NCT00300274,https://clinicaltrials.gov/show/NCT00300274,Graft_Rejection,everolimus|mycophenolate_mofetil|cyclosporine|corticosteroids|,3,547,serious_events,arm0,Everolimus 1.5 mg,2,279
Drug_hypersensitivity,Immune_system_disorders,NCT00300274,https://clinicaltrials.gov/show/NCT00300274,Graft_Rejection,everolimus|mycophenolate_mofetil|cyclosporine|corticosteroids|,3,547,serious_events,arm2,Mycophenolate Mofetil,1,268
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00303459,https://clinicaltrials.gov/show/NCT00303459,Pulmonary_Arterial_Hypertension,bosentan|placebo|,2,333,serious_events,arm0,Bosentan,1,159
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00303459,https://clinicaltrials.gov/show/NCT00303459,Pulmonary_Arterial_Hypertension,bosentan|placebo|,2,333,serious_events,arm1,Placebo,1,174
Drug_hypersensitivity,Immune_system_disorders,NCT00307437,https://clinicaltrials.gov/show/NCT00307437,Psoriasis,Placebo;_Ustekinumab_(CNTO_1275)_45_or_90_mg|Ustekinumab_(CNTO_1275)_45_mg|Ustekinumab_(CNTO_1275)_90_mg|,1,195,serious_events,arm4,Placebo -> Ustekinumab 90 mg (After CP),1,195
Drug_hypersensitivity,Immune_system_disorders,NCT00308087,https://clinicaltrials.gov/show/NCT00308087,Lymphoma_Follicular,Sargramostim_(Leukine)|Rituximab|,1,38,other_events,arm1,Rituximab + Sargramostim,1,38
Drug_Hypersensitivity,Immune_system_disorders,NCT00312377,https://clinicaltrials.gov/show/NCT00312377,Non-small_Cell_Lung_Cancer|Lung_Cancer|,Docetaxel|Vandetanib|,3,1391,serious_events,arm0,Vandetanib 100 mg Plus Docetaxel,2,694
Drug_Hypersensitivity,Immune_system_disorders,NCT00312377,https://clinicaltrials.gov/show/NCT00312377,Non-small_Cell_Lung_Cancer|Lung_Cancer|,Docetaxel|Vandetanib|,3,1391,serious_events,arm1,Placebo Plus Docetaxel,1,697
Drug_Hypersensitivity,Immune_system_disorders,NCT00312858,https://clinicaltrials.gov/show/NCT00312858,Hepatitis_A_Virus,Comparator:_VAQTA_ ¢_(Hepatitis_A_vaccine)|Comparator:_ProQuad_ ¢_(Measles_Mumps_Rubella_and_Varicella_vaccine)|Comparator:_Prevnar_ ¢_(Pneumococcal_7-Valent_Conjugate_vaccine)|,1,330,other_events,arm0,Arm 1: VAQTA_ ¢ + ProQuad_ ¢ + Prevnar_ ¢,1,330
Drug_hypersensitivity,Immune_system_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,1,102,other_events,arm1,Docetaxel+Prednisone,1,102
Drug_Hypersensitivity,Immune_system_disorders,NCT00314145,https://clinicaltrials.gov/show/NCT00314145,Japanese_Encephalitis,ChimeriVax_ ¢-JE|JE-VAX‘Œ|,1,410,serious_events,arm0,JE-VAX‘Œ,1,410
Drug_hypersensitivity,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,6,63,other_events,arm5,Phase 1 - Total,2,25
Drug_hypersensitivity,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,6,63,other_events,arm3,Phase 1 - Cohort 4,2,10
Drug_hypersensitivity,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,6,63,serious_events,arm5,Phase 1 - Total,1,25
Drug_hypersensitivity,Immune_system_disorders,NCT00315705,https://clinicaltrials.gov/show/NCT00315705,Acute_Lymphoblastic_Leukemia|Acute_Myelogenous_Leukemia|Relapsed_Leukemia|,clofarabine|Etoposide|Cyclophosphamide|,6,63,serious_events,arm1,Phase 1 - Cohort 2,1,3
Drug_hypersensitivity,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,15,132,other_events,arm0,Dose-finding Phase,2,22
Drug_hypersensitivity,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,15,132,serious_events,arm1,Activity Assessment Phase,1,55
Drug_hypersensitivity,Immune_system_disorders,NCT00316173,https://clinicaltrials.gov/show/NCT00316173,Ovarian_Cancer|Neoplasms_Ovarian|,topotecan|CARBOPLATIN|,15,132,other_events,arm1,Activity Assessment Phase,12,55
Drug_hypersensitivity,Immune_system_disorders,NCT00317226,https://clinicaltrials.gov/show/NCT00317226,Anemia,Ferric_Carboxymaltose_(FCM),1,127,serious_events,arm0,Ferric Carboxymaltose (FCM),1,127
Drug_hypersensitivity,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,20,632,other_events,arm1,Placebo and Cytarabine,1,155
Drug_hypersensitivity,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,20,632,other_events,arm0,Clofarabine (IV Formulation) and Cytarabine,9,161
Drug_hypersensitivity,Immune_system_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,20,632,other_events,arm2,Overall,10,316
Drug_hypersensitivity,Immune_system_disorders,NCT00321464,https://clinicaltrials.gov/show/NCT00321464,Bone_Metastases,Denosumab|Zoledronic_Acid|,1,1013,serious_events,arm0,Zoledronic Acid 4 mg Q4W,1,1013
Drug_hypersensitivity,Immune_system_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,1,14,other_events,arm2,Part A Romiplostim 750 ‘µg,1,14
Drug_Hypersensitivity,Immune_system_disorders,NCT00322452,https://clinicaltrials.gov/show/NCT00322452,Non-Small_Cell_Lung_Cancer,Gefitinib|Carboplatin|Paclitaxel|,4,1196,serious_events,arm1,Carboplatin/Paclitaxel,3,589
Drug_Hypersensitivity,Immune_system_disorders,NCT00322452,https://clinicaltrials.gov/show/NCT00322452,Non-Small_Cell_Lung_Cancer,Gefitinib|Carboplatin|Paclitaxel|,4,1196,serious_events,arm0,Gefitinib,1,607
Drug_hypersensitivity,Immune_system_disorders,NCT00323609,https://clinicaltrials.gov/show/NCT00323609,Vertebral_Body_Compression_Fractures,Vertebroplasty|Kyphoplasty|,1,190,serious_events,arm1,Vertebroplasty,1,190
Drug_hypersensitivity,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,3,286,other_events,arm0,Early AMD,1,107
Drug_hypersensitivity,Immune_system_disorders,NCT00327470,https://clinicaltrials.gov/show/NCT00327470,Age_Related_Macular_Degeneration_(AMD)|Macular_Degeneration|Choroidal_Neovascularization_(CNV)|,Pegaptanib_Sodium_0.3_mg,3,286,other_events,arm1,Established AMD,2,179
Drug_hypersensitivity,Immune_system_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,1,86,other_events,arm0,Alemtuzumab 30mg,1,86
Drug_hypersensitivity,Immune_system_disorders,NCT00329550,https://clinicaltrials.gov/show/NCT00329550,Crohn's_Disease,Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|,6,104,other_events,arm3,Total 1 (This Extension Study Only),2,40
Drug_hypersensitivity,Immune_system_disorders,NCT00329550,https://clinicaltrials.gov/show/NCT00329550,Crohn's_Disease,Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|,6,104,other_events,arm4,Total 2 (Treatment With CZP in Main Study and Extension Study),2,40
Drug_hypersensitivity,Immune_system_disorders,NCT00329550,https://clinicaltrials.gov/show/NCT00329550,Crohn's_Disease,Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|,6,104,other_events,arm0,CZP 400 mg / Placebo,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00329550,https://clinicaltrials.gov/show/NCT00329550,Crohn's_Disease,Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|Certolizumab_pegol_(CZP)|,6,104,other_events,arm1,CZP 400 mg / CZP 200 mg,1,15
Drug_hypersensitivity,Immune_system_disorders,NCT00330759,https://clinicaltrials.gov/show/NCT00330759,Bone_Metastases,Denosumab|Zoledronic_Acid|,3,878,serious_events,arm1,Denosumab 120 mg Q4W,3,878
Drug_hypersensitivity,Immune_system_disorders,NCT00333840,https://clinicaltrials.gov/show/NCT00333840,Chronic_Myelogenous_Leukemia,imatinib_mesilate|interferon-alpha_(INF-a)|cytarabine_(ARA-C)|,1,551,serious_events,arm0,Imatinib (STI571),1,551
Drug_hypersensitivity,Immune_system_disorders,NCT00337675,https://clinicaltrials.gov/show/NCT00337675,Asthma,montelukast_sodium|Comparator:_Placebo_(unspecified)|montelukast_sodium|,1,588,serious_events,arm1,Intermittent Montelukast,1,588
Drug_hypersensitivity,Immune_system_disorders,NCT00339144,https://clinicaltrials.gov/show/NCT00339144,Tumors,Dasatinib|Dasatinib|Dasatinib|,1,9,other_events,arm0,Dasatinib 100 mg,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00339183,https://clinicaltrials.gov/show/NCT00339183,Metastatic_Colorectal_Cancer,Panitumumab|FOLFIRI|,1,594,serious_events,arm1,FOLFIRI Alone,1,594
Drug_hypersensitivity,Immune_system_disorders,NCT00346398,https://clinicaltrials.gov/show/NCT00346398,Asthma|Allergic_Sensitization|,Oral_mucosal_immunoprophylaxis_(OMIP)|Placebo|,3,51,other_events,arm0,OMIP With Timothy Grass Cat and House Dust Mite Allergens,2,25
Drug_hypersensitivity,Immune_system_disorders,NCT00346398,https://clinicaltrials.gov/show/NCT00346398,Asthma|Allergic_Sensitization|,Oral_mucosal_immunoprophylaxis_(OMIP)|Placebo|,3,51,other_events,arm1,Placebo,1,26
Drug_hypersensitivity,Immune_system_disorders,NCT00350792,https://clinicaltrials.gov/show/NCT00350792,Non_Small_Cell_Lung_Cancer,pemetrexed|carboplatin|,1,62,serious_events,arm0,Pemetrexed + Carboplatin,1,62
Drug_hypersensitivity,Immune_system_disorders,NCT00355134,https://clinicaltrials.gov/show/NCT00355134,Multiple_Sclerosis,Fingolimod|Placebo|,1,355,serious_events,arm2,Core: Placebo,1,355
Drug_hypersensitivity,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,2,20,other_events,arm1,Less Than One Year: Pemetrexed + Gemcitabine,1,11
Drug_hypersensitivity,Immune_system_disorders,NCT00356525,https://clinicaltrials.gov/show/NCT00356525,Lung_Neoplasms,pemetrexed|gemcitabine|carboplatin|Pemetrexed|,2,20,other_events,arm3,One Year or Greater: Pemetrexed + Gemcitabine,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00357903,https://clinicaltrials.gov/show/NCT00357903,Rheumatoid_Arthritis,Etanercept,1,58,serious_events,arm1,Pediatric Subjects,1,58
Drug_hypersensitivity,Immune_system_disorders,NCT00358436,https://clinicaltrials.gov/show/NCT00358436,Chronic_Obstructive_Pulmonary_Disease_(COPD),Aclidinium_bromide|Placebo|,1,600,serious_events,arm0,Aclidinium Bromide 200 •_g Once-daily,1,600
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00358670,https://clinicaltrials.gov/show/NCT00358670,Psoriasis,infliximab|infliximab|,1,222,serious_events,arm0,Maintenance Infliximab,1,222
Drug_hypersensitivity,Immune_system_disorders,NCT00358917,https://clinicaltrials.gov/show/NCT00358917,Human_Immunodeficiency_Virus_Infections,lopinavir/ritonavir_(LPV/r)_tablet_with_nucleoside/nucleotide_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_tablet_with_nucleoside/nucleotide_reverse_transcriptase_inhibitors_(NRTIs)|,1,299,serious_events,arm1,LPV/r 400/100 mg BID Tablet,1,299
Drug_hypersensitivity,Immune_system_disorders,NCT00359021,https://clinicaltrials.gov/show/NCT00359021,HIV-1,TMC125,2,759,serious_events,arm0,DUET PLACEBO,1,256
Drug_hypersensitivity,Immune_system_disorders,NCT00359021,https://clinicaltrials.gov/show/NCT00359021,HIV-1,TMC125,2,759,serious_events,arm2,All Participants,1,503
Drug_hypersensitivity,Immune_system_disorders,NCT00359424,https://clinicaltrials.gov/show/NCT00359424,Stroke,IV_rt-PA_alone|endovascular_therapy|,1,434,other_events,arm0,Endovascular,1,434
Drug_hypersensitivity,Immune_system_disorders,NCT00359801,https://clinicaltrials.gov/show/NCT00359801,Diabetes_Mellitus,Randomization_to_Exubera_(insulin_human_[rDNA_origin]_inhalation_powder)_or_Usual_Diabetes_Care|Randomization_to_Exubera_(insulin_human_[rDNA_origin]_inhalation_powder)_or_Usual_Diabetes_Care|,1,987,serious_events,arm0,Exubera‘Œ,1,987
Drug_hypersensitivity,Immune_system_disorders,NCT00362232,https://clinicaltrials.gov/show/NCT00362232,Venous_Thromboembolism,Rivaroxaban_(Xarelto_BAY59-7939)|Enoxaparin|Placebo:_tablet_of_Rivaroxaban|Placebo:_syringes_of_Enoxaparin|,1,1526,serious_events,arm0,Rivaroxaban 10 mg Once Daily (OD) (Xarelto BAY59-7939),1,1526
Drug_hypersensitivity,Immune_system_disorders,NCT00363415,https://clinicaltrials.gov/show/NCT00363415,Small_Cell_Lung_Cancer,pemetrexed|etoposide|carboplatin|,1,447,serious_events,arm1,Etoposide + Carboplatin,1,447
Drug_hypersensitivity,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,4,1169,serious_events,arm0,Panitumumab Plus FOLFOX,2,585
Drug_hypersensitivity,Immune_system_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,4,1169,serious_events,arm1,FOLFOX Alone,2,584
Drug_hypersensitivity,Immune_system_disorders,NCT00366340,https://clinicaltrials.gov/show/NCT00366340,Vaccines_Pneumococcal,13-valent_pneumococcal_conjugate_vaccine|7-valent_pneumococcal_conjugate_vaccine|,1,287,other_events,arm7,7vPnC 6-Month Follow-up,1,287
Drug_Hypersensitivity,Immune_system_disorders,NCT00367432,https://clinicaltrials.gov/show/NCT00367432,Epilepsies|Partial|,Levetiracetam,1,398,serious_events,arm0,Levetiracetam,1,398
Drug_hypersensitivity,Immune_system_disorders,NCT00367484,https://clinicaltrials.gov/show/NCT00367484,Relapsing_Remitting_Multiple_Sclerosis,Rebif‘Œ_(clone_484-39),1,460,serious_events,arm0,Rebif‘Œ (Clone 484-39),1,460
Drug_hypersensitivity,Immune_system_disorders,NCT00369824,https://clinicaltrials.gov/show/NCT00369824,Human_Papillomavirus_Type-16/-18_Infection|Papillomavirus_Vaccines|Cervical_Neoplasia|,Different_formulations_of_GSK_Biologicals'_HPV_vaccine_(580299)|Menactra_TM|Boostrix_TM|,1,214,serious_events,arm4,Menactra/Cervarix Group,1,214
Drug_hypersensitivity,Immune_system_disorders,NCT00370552,https://clinicaltrials.gov/show/NCT00370552,Metastatic_Breast_Cancer,Ixabepilone_16_mg/m^2_+_Bevacizumab_10_mg/kg|Ixabepilone_40_mg/m^2_+_Bevacizumab_15_mg/kg|Paclitaxel_90_mg/m^2_+_Bevacizumab_10_mg/kg|,2,32,other_events,arm2,Paclitaxel 90 mg/m^2 + Bevacizumab 10 mg/kg,2,32
Drug_hypersensitivity,Immune_system_disorders,NCT00372424,https://clinicaltrials.gov/show/NCT00372424,Breast_Cancer,Herceptin|Sunitinib|Taxotere|,3,25,other_events,arm0,Sunitinib + Docetaxel + Trastuzumab,3,25
Drug_hypersensitivity,Immune_system_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,1,238,other_events,arm0,Sunitinib,1,238
Drug_hypersensitivity,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,9,712,other_events,arm1,Bevacizumab + Paclitaxel,4,242
Drug_hypersensitivity,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,9,712,serious_events,arm0,Sunitinib + Paclitaxel,1,235
Drug_hypersensitivity,Immune_system_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,9,712,other_events,arm0,Sunitinib + Paclitaxel,4,235
Drug_hypersensitivity,Immune_system_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,6,112,other_events,arm0,Clofarabine,6,112
Drug_hypersensitivity,Immune_system_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,1,332,other_events,arm0,13vPnC Infant Series,1,332
Drug_hypersensitivity,Immune_system_disorders,NCT00374322,https://clinicaltrials.gov/show/NCT00374322,Neoplasms_Breast,lapatinib|placebo|,1,1573,serious_events,arm0,Lapatinib 1500 mg,1,1573
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00375505,https://clinicaltrials.gov/show/NCT00375505,Breast_Cancer,Zoledronic_acid|Placebo|,1,34,serious_events,arm1,Zometa,1,34
Drug_Hypersensitivity,Immune_system_disorders,NCT00378573,https://clinicaltrials.gov/show/NCT00378573,Non-small_Cell_Lung_Cancer,docetaxel|gemcitabine|bevacizumab|,1,17,other_events,arm0,Docetaxel Gemcitabine and Bevacizumab,1,17
drug_hypersensitivity,General_disorders,NCT00380068,https://clinicaltrials.gov/show/NCT00380068,Pulmonary_Hypertension,Ambrisentan,1,224,serious_events,arm0,Ambrisentan,1,224
Drug_Hypersensitivity,Immune_system_disorders,NCT00379769,https://clinicaltrials.gov/show/NCT00379769,Diabetes_Mellitus_Type_2,Rosiglitazone|Sulfonylurea|Metformin|,1,1117,serious_events,arm0,RSG in Addition to Background MET,1,1117
Drug_hypersensitivity,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,5,61,other_events,arm0,Pregabalin,2,32
Drug_hypersensitivity,Immune_system_disorders,NCT00380874,https://clinicaltrials.gov/show/NCT00380874,Chemotherapy-Induced_Peripheral_Neuropathy,Pregabalin|Placebo|,5,61,other_events,arm1,Placebo,3,29
Drug_Hypersensitivity,Immune_system_disorders,NCT00381303,https://clinicaltrials.gov/show/NCT00381303,HIV|Infectious|,darunavir|ritonavir|,2,429,serious_events,arm0,Female,1,287
Drug_Hypersensitivity,Immune_system_disorders,NCT00381303,https://clinicaltrials.gov/show/NCT00381303,HIV|Infectious|,darunavir|ritonavir|,2,429,serious_events,arm1,Male,1,142
Drug_hypersensitivity,Immune_system_disorders,NCT00384059,https://clinicaltrials.gov/show/NCT00384059,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|Pediacel|NeisVac-C|Menitorix|,1,130,other_events,arm4,13vPnC Toddler Series,1,130
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,other_events,arm2,1Bevacizumab 5mg/kg,50,704
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,serious_events,arm1,Cediranib 30 mg,1,191
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,other_events,arm0,Cediranib 20 mg,41,705
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,serious_events,arm2,1Bevacizumab 5mg/kg,5,704
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,other_events,arm1,Cediranib 30 mg,10,191
Drug_Hypersensitivity,Immune_system_disorders,NCT00384176,https://clinicaltrials.gov/show/NCT00384176,Colorectal_Cancer,Cediranib|Bevacizumab|5-fluorouracil_(_in_FOLFOX)|Leucovorin_(in_FOLFOX)|Oxaliplatin_(in_FOLFOX)|,109,3200,serious_events,arm0,Cediranib 20 mg,2,705
Drug_hypersensitivity,Immune_system_disorders,NCT00389207,https://clinicaltrials.gov/show/NCT00389207,HIV_Infections,nevirapine_bid|nevirapine_qd|atazanavir|,1,188,serious_events,arm0,Nevirapine QD,1,188
Drug_hypersensitivity,Immune_system_disorders,NCT00390858,https://clinicaltrials.gov/show/NCT00390858,Transfusional_Iron_Overload|•_-thalassemia_Major|Pediatric_Rare_Anemia|,Deferasirox,1,20,other_events,arm1,Adolescents ( ___12 Years),1,20
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00391443,https://clinicaltrials.gov/show/NCT00391443,Idiopathic_Pulmonary_Fibrosis,Bosentan|Placebo|,1,406,serious_events,arm1,Bosentan,1,406
Drug_hypersensitivity,Immune_system_disorders,NCT00391625,https://clinicaltrials.gov/show/NCT00391625,Gaucher_Disease_Type_1,GA-GCB,2,10,other_events,arm0,GA-GCB,2,10
Drug_Hypersensitivity,Immune_system_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,4,18624,serious_events,arm0,TICAGRELOR,1,9333
Drug_Hypersensitivity,Immune_system_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,4,18624,serious_events,arm1,CLOPIDOGREL,3,9291
Drug_hypersensitivity,Immune_system_disorders,NCT00394836,https://clinicaltrials.gov/show/NCT00394836,Lymphoma_Follicular,Ofatumumab|Ofatumumab|,1,86,serious_events,arm1,Ofatumumab 1000 mg,1,86
Drug_hypersensitivity,Immune_system_disorders,NCT00395135,https://clinicaltrials.gov/show/NCT00395135,Obesity,Lorcaserin_10_mg_BID|Matching_Placebo_BID|,1,573,serious_events,arm2,Year 2 - Lorc 10 mg BID (Yr 1) / Lorc 10 mg BID (Yr 2),1,573
Drug_hypersensitivity,Immune_system_disorders,NCT00395629,https://clinicaltrials.gov/show/NCT00395629,Iron_Overload|Hereditary_Hemochromatosis|,Deferasirox_(ICL670),2,20,other_events,arm3,Deferasirox (ICL670) 5 mg/kg/day_Extension Study,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00395629,https://clinicaltrials.gov/show/NCT00395629,Iron_Overload|Hereditary_Hemochromatosis|,Deferasirox_(ICL670),2,20,other_events,arm0,Deferasirox (ICL670) 5 mg/kg/day_Core Study,1,11
Drug_Hypersensitivity,Immune_system_disorders,NCT00396318,https://clinicaltrials.gov/show/NCT00396318,Dysfunctional_Central_Venous_Access_Catheters,tenecteplase,1,246,other_events,arm0,Tenecteplase,1,246
Drug_hypersensitivity,Immune_system_disorders,NCT00396981,https://clinicaltrials.gov/show/NCT00396981,Intracranial_Aneurysms,Matrix_2‘Œ_coils_for_endovascular_aneurysm_occlusion|GDC‘Œ_coils_for_endovascular_aneurysm_occlusion|,2,630,serious_events,arm1,GDC‘Œ Coils for Endovascular Aneurysm Occlusion,1,315
Drug_hypersensitivity,Immune_system_disorders,NCT00396981,https://clinicaltrials.gov/show/NCT00396981,Intracranial_Aneurysms,Matrix_2‘Œ_coils_for_endovascular_aneurysm_occlusion|GDC‘Œ_coils_for_endovascular_aneurysm_occlusion|,2,630,other_events,arm1,GDC‘Œ Coils for Endovascular Aneurysm Occlusion,1,315
drug_hypersensitivity,Immune_system_disorders,NCT00398216,https://clinicaltrials.gov/show/NCT00398216,Thrombosis|Hip_Replacement|,DU176b_-_action_is_the_prevention_of_venous_thromboembolism_by_the_use_of_a_Factor_Xa_inhibitor,1,172,serious_events,arm4,Dalteparin,1,172
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,other_events,arm1,Cediranib 20mg,24,500
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,serious_events,arm0,Cediranib 30mg,1,214
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,other_events,arm0,Cediranib 30mg,6,214
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,serious_events,arm2,Placebo,2,358
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,serious_events,arm1,Cediranib 20mg,3,500
Drug_Hypersensitivity,Immune_system_disorders,NCT00399035,https://clinicaltrials.gov/show/NCT00399035,Metastatic_Colorectal_Cancer,Cediranib|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|XELOX_(Capecitabine_and_Oxaliplatin)|Cediranib_Placebo|,55,2144,other_events,arm2,Placebo,19,358
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00400764,https://clinicaltrials.gov/show/NCT00400764,Non-Hodgkin's_Lymphoma,Dulanermin|Rituximab|,2,26,other_events,arm3,Phase II - Combination Therapy,2,26
Drug_hypersensitivity,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,2,83,serious_events,arm0,Temozolomide + Irinotecan for Medulloblastoma,1,66
Drug_hypersensitivity,Immune_system_disorders,NCT00404495,https://clinicaltrials.gov/show/NCT00404495,Glioma|Medulloblastoma|,Irinotecan|Temozolomide|,2,83,other_events,arm1,Temozolomide + Irinotecan for High-Grade Glioma,1,17
Drug_Hypersensitivity,Immune_system_disorders,NCT00404924,https://clinicaltrials.gov/show/NCT00404924,Non-Small-Cell_Lung_Carcinoma,ZD6474_(vandetanib)|Best_Supportive_Care|,2,619,serious_events,arm0,Vandetanib,2,619
Drug_Hypersensitivity,Immune_system_disorders,NCT00403767,https://clinicaltrials.gov/show/NCT00403767,Atrial_Fibrillation|Stroke|Embolism|,Rivaroxaban|Warfarin|Matching_placebo_for_Rivaroxaban_arm_(Warfarin_placebo)|Matching_placebo_for_Warfarin_arm_(Rivaroxaban_placebo)|,3,14236,serious_events,arm0,Rivaroxaban,2,7111
Drug_Hypersensitivity,Immune_system_disorders,NCT00403767,https://clinicaltrials.gov/show/NCT00403767,Atrial_Fibrillation|Stroke|Embolism|,Rivaroxaban|Warfarin|Matching_placebo_for_Rivaroxaban_arm_(Warfarin_placebo)|Matching_placebo_for_Warfarin_arm_(Rivaroxaban_placebo)|,3,14236,serious_events,arm1,Warfarin,1,7125
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00406653,https://clinicaltrials.gov/show/NCT00406653,Crohn's_Disease,abatacept|placebo|abatacept|,1,128,serious_events,arm5,Placebo (IP),1,128
Drug_hypersensitivity,Immune_system_disorders,NCT00408876,https://clinicaltrials.gov/show/NCT00408876,Back_Pain_Without_Radiation,Duloxetine|Placebo|,1,59,other_events,arm0,Duloxetine 20 mg,1,59
Drug_hypersensitivity,Immune_system_disorders,NCT00412061,https://clinicaltrials.gov/show/NCT00412061,Carcinoid_Tumor|Malignant_Carcinoid_Syndrome|,Octreotide|Placebo|Everolimus|,1,170,serious_events,arm2,Everolimus Open Label,1,170
Drug_hypersensitivity,Immune_system_disorders,NCT00412984,https://clinicaltrials.gov/show/NCT00412984,Atrial_Fibrillation|Atrial_Flutter|,warfarin|apixaban|,2,18140,serious_events,arm1,Apixaban,1,9052
Drug_hypersensitivity,Immune_system_disorders,NCT00412984,https://clinicaltrials.gov/show/NCT00412984,Atrial_Fibrillation|Atrial_Flutter|,warfarin|apixaban|,2,18140,serious_events,arm0,Warfarin,1,9088
Drug_hypersensitivity,Immune_system_disorders,NCT00417963,https://clinicaltrials.gov/show/NCT00417963,Carotid_Artery_Stenosis,Carotid_Artery_Stenting,2,486,serious_events,arm0,ViVexx Carotid Stent Group,2,486
Drug_hypersensitivity,Immune_system_disorders,NCT00420849,https://clinicaltrials.gov/show/NCT00420849,Multiple_Myeloma,Lenalidomide|Dexamethasone|,1,587,serious_events,arm0,Lenalidomide Plus Dexamethasone,1,587
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,serious_events,arm0,Part A: Dose Escalation (N=23),1,23
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,serious_events,arm1,Part B: Ovarian Cancer MTD (N=35),2,35
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,other_events,arm2,Part C: 3-6 Hours Infusion (N=7),3,7
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,other_events,arm0,Part A: Dose Escalation (N=23),2,23
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,other_events,arm3,Part D: Bladder Cancer MTD (N=15),4,15
Drug_hypersensitivity,Immune_system_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,20,138,other_events,arm1,Part B: Ovarian Cancer MTD (N=35),8,35
Drug_hypersensitivity,Immune_system_disorders,NCT00422734,https://clinicaltrials.gov/show/NCT00422734,Impotence,tadalafil|Placebo|,1,78,other_events,arm0,Placebo,1,78
Drug_hypersensitivity,Immune_system_disorders,NCT00423449,https://clinicaltrials.gov/show/NCT00423449,Non-Small_Cell_Lung_Cancer,vorinostat|Gemcitabine|Platinum-based_agent|,1,18,other_events,arm2,MK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin,1,18
drug_hypersensitivity,Immune_system_disorders,NCT00423592,https://clinicaltrials.gov/show/NCT00423592,Pulmonary_Hypertension,ambrisentan,2,36,other_events,arm0,Ambrisentan,2,36
Drug_hypersensitivity,Immune_system_disorders,NCT00424476,https://clinicaltrials.gov/show/NCT00424476,Systemic_Lupus_Erythematosus,Placebo|Belimumab_1_mg/kg|Belimumab_10_mg/kg|,1,290,serious_events,arm2,Belimumab 10 mg/kg,1,290
Drug_hypersensitivity,Immune_system_disorders,NCT00425061,https://clinicaltrials.gov/show/NCT00425061,Asthma,IMA-638|IMA-638|placebo|,1,45,other_events,arm4,IMA-638 200 mg: Stage 2 and 3,1,45
Drug_hypersensitivity,Immune_system_disorders,NCT00426660,https://clinicaltrials.gov/show/NCT00426660,Advanced_HIV_Infection,maraviroc,3,1032,other_events,arm0,Maraviroc,3,1032
Drug_Hypersensitivity,Immune_system_disorders,NCT00428584,https://clinicaltrials.gov/show/NCT00428584,Relapsing_Remitting_Multiple_Sclerosis_(RRMS),New_Formulation_of_rebif_-_human_interferon_beta-1a|Interferon_beta_-1b|,1,65,other_events,arm0,New Formulation of Rebif,1,65
Drug_hypersensitivity,Immune_system_disorders,NCT00427895,https://clinicaltrials.gov/show/NCT00427895,Pneumococcal_Infections,13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|23-valent_Pneumococcal_Polysaccharide_Vaccine_(23vPS)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|23-valent_Pneumococcal_Polysaccharide_Vaccine_(23vPS)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|,1,899,other_events,arm14,13vPnC Cohort 3,1,899
Drug_hypersensitivity,Immune_system_disorders,NCT00430716,https://clinicaltrials.gov/show/NCT00430716,Pulmonary_Arterial_Hypertension,Sildenafil_citrate|Sildenafil_citrate|Sildenafil_citrate|Sildenafil_citrate|,2,90,serious_events,arm2,Sildenafil 20 mg,1,45
Drug_hypersensitivity,Immune_system_disorders,NCT00432159,https://clinicaltrials.gov/show/NCT00432159,Cervical_Degenerative_Disc_Disease,Cervical_TDR|ACDF_with_plate|,3,391,other_events,arm0,1-level Cervical TDR,1,186
Drug_hypersensitivity,Immune_system_disorders,NCT00432159,https://clinicaltrials.gov/show/NCT00432159,Cervical_Degenerative_Disc_Disease,Cervical_TDR|ACDF_with_plate|,3,391,other_events,arm2,2-level Cervical TDR,1,39
Drug_hypersensitivity,Immune_system_disorders,NCT00432159,https://clinicaltrials.gov/show/NCT00432159,Cervical_Degenerative_Disc_Disease,Cervical_TDR|ACDF_with_plate|,3,391,other_events,arm1,1-level ACDF With Plate,1,166
Drug_Hypersensitivity,Immune_system_disorders,NCT00434252,https://clinicaltrials.gov/show/NCT00434252,Melanoma,bevacizumab|carboplatin|paclitaxel|placebo|,1,69,serious_events,arm0,Carboplatin+Paclitaxel+Placebo,1,69
Drug_Hypersensitivity,Immune_system_disorders,NCT00434356,https://clinicaltrials.gov/show/NCT00434356,Metastatic_Breast_Cancer,bevacizumab|sunitinib|paclitaxel|,1,23,serious_events,arm1,Bevacizumab + Paclitaxel,1,23
Drug_Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,48,960,serious_events,arm1,Carboplatin and Gemcitabine + Placebo,3,233
Drug_Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,48,960,other_events,arm0,Carboplatin and Gemcitabine + Bevacizumab,26,247
Drug_Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,48,960,serious_events,arm0,Carboplatin and Gemcitabine + Bevacizumab,4,247
Drug_Hypersensitivity,Immune_system_disorders,NCT00434642,https://clinicaltrials.gov/show/NCT00434642,Ovarian_Cancer,Carboplatin|Gemcitabine|Bevacizumab|Placebo|,48,960,other_events,arm1,Carboplatin and Gemcitabine + Placebo,15,233
Drug_hypersensitivity,Immune_system_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,1,215,other_events,arm1,Capecitabine,1,215
Drug_hypersensitivity,Immune_system_disorders,NCT00435825,https://clinicaltrials.gov/show/NCT00435825,Hepatitis_B_Chronic,peginterferon_alfa-2a_[Pegasys],2,274,serious_events,arm0,Peginterferon Alfa-2a 90 •_g_24 Weeks,1,144
Drug_hypersensitivity,Immune_system_disorders,NCT00435825,https://clinicaltrials.gov/show/NCT00435825,Hepatitis_B_Chronic,peginterferon_alfa-2a_[Pegasys],2,274,serious_events,arm3,Peginterferon Alfa-2a 180 •_g_48 Weeks,1,130
Drug_hypersensitivity,Immune_system_disorders,NCT00438451,https://clinicaltrials.gov/show/NCT00438451,Focal_Epilepsy,Levetiracetam|Carbamazepine|Lamotrigine|,1,121,serious_events,arm1,Carbamazepine,1,121
Drug_hypersensitivity,Immune_system_disorders,NCT00439270,https://clinicaltrials.gov/show/NCT00439270,Metastatic_Prostate_Cancer,Dasatinib|Docetaxel|,1,34,serious_events,arm0,Dasatinib 100 mg + Docetaxel 75 mg/m^2,1,34
Drug_hypersensitivity,Immune_system_disorders,NCT00439569,https://clinicaltrials.gov/show/NCT00439569,Spinal_Muscular_Atrophy_Type_II|Spinal_Muscular_Atrophy_Type_III|,sodium_phenylbutyrate,1,9,other_events,arm0,Cohorts 1 & 2 (500 mg/kg/Day),1,9
Drug_hypersensitivity,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,24,451,serious_events,arm1,FOLFOX4 + Cetuximab,2,150
Drug_hypersensitivity,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,24,451,other_events,arm1,FOLFOX4 + Cetuximab,10,150
Drug_hypersensitivity,Immune_system_disorders,NCT00439517,https://clinicaltrials.gov/show/NCT00439517,Previously_Untreated_Metastatic_Colorectal_Cancer,UFOX_+_Cetuximab|FOLFOX4_+_Cetuximab|,24,451,other_events,arm0,UFOX + Cetuximab,12,151
Drug_Hypersensitivity,Immune_system_disorders,NCT00440011,https://clinicaltrials.gov/show/NCT00440011,Glaucoma|Ocular_Hypertension|,bimatoprost_0.03_PERCENT_eye_drops|travoprost_0.004_PERCENT_eye_drops|,1,133,other_events,arm1,Travoprost,1,133
Drug_hypersensitivity,Immune_system_disorders,NCT00439777,https://clinicaltrials.gov/show/NCT00439777,Pulmonary_Embolism,Rivaroxaban_(Xarelto_BAY59-7939)|Enoxaparin_overlapping_with_and_followed_by_VKA|,1,2405,serious_events,arm1,Enoxaparin/VKA,1,2405
Drug_hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,15,1303,serious_events,arm3,ABC/3TC + ATV: Extension Phase,1,189
Drug_hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,15,1303,serious_events,arm2,ABC/3TC + ATV/r: Randomization Phase,3,209
Drug_hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,15,1303,serious_events,arm1,ABC/3TC + ATV: Randomization Phase,2,210
Drug_hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,15,1303,serious_events,arm0,ABC/3TC + ATV/r: Induction Phase,5,515
Drug_hypersensitivity,Immune_system_disorders,NCT00440947,https://clinicaltrials.gov/show/NCT00440947,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)_+_ritonavir_(/r)|Abacavir_(ABC)/lamivudine_(3TC)_+_atazanavir_(ATV)|,15,1303,serious_events,arm4,ABC/3TC + ATV/r: Extension Phase,4,180
Drug_hypersensitivity,Immune_system_disorders,NCT00442962,https://clinicaltrials.gov/show/NCT00442962,HIV_Infections,Efavirenz|Emtricitabine/Tenofovir_disoproxil_fumarate|,3,54,other_events,arm0,EFV+FTC/TDF,3,54
Drug_hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,15,4828,other_events,arm6,Toddler Dose Combined 13vPnC,3,1210
Drug_hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,15,4828,other_events,arm3,Infant Series 7vPnC,1,244
Drug_hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,15,4828,other_events,arm0,Infant Series 13vPnC (Pilot Lot 1),1,486
Drug_hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,15,4828,other_events,arm8,Post Toddler Dose 6-Month Follow-up Combined 13vPnC,6,1443
Drug_hypersensitivity,Immune_system_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,15,4828,other_events,arm4,After the Infant Series Combined 13vPnC,4,1445
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,4,126,other_events,arm1,Stratum 2: TCH + Bevacizumab,2,34
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00446030,https://clinicaltrials.gov/show/NCT00446030,Breast_Neoplasms,Docetaxel|Doxorubicin|Carboplatin|Cyclophosphamide|Trastuzumab|Bevacizumab|,4,126,other_events,arm0,Stratum 1: TAC + Bevacizumab,2,92
Drug_hypersensitivity,Immune_system_disorders,NCT00449865,https://clinicaltrials.gov/show/NCT00449865,Parkinson's_Disease,creatine|placebo|,2,1741,serious_events,arm0,Placebo,1,867
Drug_hypersensitivity,Immune_system_disorders,NCT00449865,https://clinicaltrials.gov/show/NCT00449865,Parkinson's_Disease,creatine|placebo|,2,1741,serious_events,arm1,Creatine,1,874
Drug_hypersensitivity,Immune_system_disorders,NCT00450580,https://clinicaltrials.gov/show/NCT00450580,Infection_Human_Immunodeficiency_Virus_I|HIV-1_Infection|,fosamprenavir/ritonavir,46,424,other_events,arm1,FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD,8,106
Drug_hypersensitivity,Immune_system_disorders,NCT00450580,https://clinicaltrials.gov/show/NCT00450580,Infection_Human_Immunodeficiency_Virus_I|HIV-1_Infection|,fosamprenavir/ritonavir,46,424,serious_events,arm1,FPV/RTV 700/100 mg BID + ABC/3TC FDC 600/300 mg QD,8,106
Drug_hypersensitivity,Immune_system_disorders,NCT00450580,https://clinicaltrials.gov/show/NCT00450580,Infection_Human_Immunodeficiency_Virus_I|HIV-1_Infection|,fosamprenavir/ritonavir,46,424,serious_events,arm0,FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q,15,106
Drug_hypersensitivity,Immune_system_disorders,NCT00450580,https://clinicaltrials.gov/show/NCT00450580,Infection_Human_Immunodeficiency_Virus_I|HIV-1_Infection|,fosamprenavir/ritonavir,46,424,other_events,arm0,FPV/RTV 1400/100 mg Once Daily (QD) + ABC/3TC FDC 600/300 mg Q,15,106
Drug_hypersensitivity,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Axitinib_+_Capecitabine_(Cohort_6)|Axitinib_+_Capecitabine_(Cohort_7)|Axitinib_+_Gemcitabine_+_Cisplatin_(Cohort_8)|Axitinib_+_Pemetrexed_+_Cisplatin_(Cohort_9)|,2,12,other_events,arm3,Axitinib + Paclitaxel (Cohort 4),1,7
Drug_hypersensitivity,Immune_system_disorders,NCT00454649,https://clinicaltrials.gov/show/NCT00454649,Neoplasms,Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_1)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_2)|Axitinib_+_Paclitaxel_+_Carboplatin_(Cohort_3)|Axitinib_+_Paclitaxel_(Cohort_4)|Axitinib_+_Docetaxel_+_Carboplatin_(Cohort_4a)|Axitinib_+_Docetaxel_(Cohort_5)|Axitinib_+_Capecitabine_(Cohort_6)|Axitinib_+_Capecitabine_(Cohort_7)|Axitinib_+_Gemcitabine_+_Cisplatin_(Cohort_8)|Axitinib_+_Pemetrexed_+_Cisplatin_(Cohort_9)|,2,12,other_events,arm1,Axitinib + Paclitaxel + Carboplatin (Cohort 2),1,5
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00457418,https://clinicaltrials.gov/show/NCT00457418,Melanoma,PEG-Intron,1,32,serious_events,arm0,PEG-Intron,1,32
Drug_hypersensitivity,Immune_system_disorders,NCT00457392,https://clinicaltrials.gov/show/NCT00457392,Carcinoma_Non-Small_Cell_Lung,erlotinib|sunitinib|erlotinib|placebo|,2,477,other_events,arm1,Erlotinib,2,477
Drug_Hypersensitivity,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,7,228,serious_events,arm0,Cisplatin and Cetuximab,1,114
Drug_Hypersensitivity,Immune_system_disorders,NCT00463788,https://clinicaltrials.gov/show/NCT00463788,Breast_Neoplasm,cetuximab_cisplatin|cisplatin|,7,228,other_events,arm0,Cisplatin and Cetuximab,6,114
Drug_hypersensitivity,Immune_system_disorders,NCT00463567,https://clinicaltrials.gov/show/NCT00463567,Pulmonary_Disease_Chronic_Obstructive|COPD|Lung_Diseases_Obstructive|,Indacaterol|Formoterol_(12_‘µg_b.i.d.)|Tiotropium_(18_‘µg_o.d.)|Placebo_to_Indacaterol|Placebo_to_Formoterol|,1,122,serious_events,arm5,Indacaterol 600 ‘µg (Not Continued Into Stage 2),1,122
Drug_hypersensitivity,Immune_system_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,2,11798,serious_events,arm0,Synflorix Group,2,11798
Drug_hypersensitivity,Immune_system_disorders,NCT00473382,https://clinicaltrials.gov/show/NCT00473382,Diabetes_Mellitus|Macular_Edema|,Ranibizumab|Sham_injection|,18,587,other_events,arm2,Ranibizumab 0.3 mg - Months 0-36,2,125
Drug_hypersensitivity,Immune_system_disorders,NCT00473382,https://clinicaltrials.gov/show/NCT00473382,Diabetes_Mellitus|Macular_Edema|,Ranibizumab|Sham_injection|,18,587,other_events,arm3,Ranibizumab 0.5 mg - Months 0-36,1,124
Drug_hypersensitivity,Immune_system_disorders,NCT00473382,https://clinicaltrials.gov/show/NCT00473382,Diabetes_Mellitus|Macular_Edema|,Ranibizumab|Sham_injection|,18,587,other_events,arm6,Ranibizumab 0.5 mg - Months 37-60,2,84
Drug_hypersensitivity,Immune_system_disorders,NCT00473382,https://clinicaltrials.gov/show/NCT00473382,Diabetes_Mellitus|Macular_Edema|,Ranibizumab|Sham_injection|,18,587,other_events,arm1,Sham Injection/Ranibizumab 0.5 mg - Months 0-36,7,127
Drug_hypersensitivity,Immune_system_disorders,NCT00473382,https://clinicaltrials.gov/show/NCT00473382,Diabetes_Mellitus|Macular_Edema|,Ranibizumab|Sham_injection|,18,587,other_events,arm0,Sham Injection - Months 0-24,6,127
Drug_hypersensitivity,Immune_system_disorders,NCT00474786,https://clinicaltrials.gov/show/NCT00474786,Renal_Cell_Carcinoma,Sorafenib|temsirolimus_(Torisel)|,1,252,serious_events,arm1,Sorafenib,1,252
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00474526,https://clinicaltrials.gov/show/NCT00474526,Meningitis_Meningococcal,Meningococcal_ACWY_Conjugate_Vaccine|DTaP-IPV-HBV|Hib|Rotavirus|Pneumococcal_7-valent_Conjugate_Vaccine|HAV|MMR-V|DTaP|,2,3021,serious_events,arm0,US1+US3,1,995
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00474526,https://clinicaltrials.gov/show/NCT00474526,Meningitis_Meningococcal,Meningococcal_ACWY_Conjugate_Vaccine|DTaP-IPV-HBV|Hib|Rotavirus|Pneumococcal_7-valent_Conjugate_Vaccine|HAV|MMR-V|DTaP|,2,3021,serious_events,arm3,LA1+LA3+LA5,1,2026
Drug_hypersensitivity,Immune_system_disorders,NCT00478647,https://clinicaltrials.gov/show/NCT00478647,Gaucher_Disease_Type_1,GA-GCB_(velaglucerase_alfa),1,40,serious_events,arm0,GA-GCB (Velaglucerase Alfa),1,40
Drug_hypersensitivity,Immune_system_disorders,NCT00479388,https://clinicaltrials.gov/show/NCT00479388,Primary_Hypercholesterolemia|Mixed_Dyslipidemia|,Comparator:_simvastatin|niacin_(+)_laropiprant|Comparator:_atorvastatin_calcium|,2,1204,serious_events,arm0,ER Niacin/Laropiprant + Run-in Statin,1,602
Drug_hypersensitivity,Immune_system_disorders,NCT00479388,https://clinicaltrials.gov/show/NCT00479388,Primary_Hypercholesterolemia|Mixed_Dyslipidemia|,Comparator:_simvastatin|niacin_(+)_laropiprant|Comparator:_atorvastatin_calcium|,2,1204,other_events,arm0,ER Niacin/Laropiprant + Run-in Statin,1,602
Drug_Hypersensitivity,Immune_system_disorders,NCT00483574,https://clinicaltrials.gov/show/NCT00483574,Meningococcal_Meningitis|Measles|Mumps|Rubella|Varicella|,Menactra‘Œ:_Meningococcal_Polysaccharide_Diphtheria_Toxoid_Conjugate|Measles-mumps-rubella-varicella_vaccine|Routine_paediatric_vaccine_-_Pneumococcal_conjugate_(PCV)_and_Hepatitis_A|,1,321,serious_events,arm1,Group 2: Routine Pediatric Vaccines,1,321
Drug_hypersensitivity,Immune_system_disorders,NCT00484315,https://clinicaltrials.gov/show/NCT00484315,Coronary_Artery_Disease,Percutaneous_coronary_intervention_(PCI)_with_paclitaxel-eluting_stent_(TAXUS_Element)_implantation|Percutaneous_coronary_intervention_(PCI)_with_paclitaxel-eluting_stent_(TAXUS_Express)_placement|,1,942,serious_events,arm0,TAXUS Element,1,942
Drug_Hypersensitivity,Immune_system_disorders,NCT00485173,https://clinicaltrials.gov/show/NCT00485173,Degenerative_Disc_Disease,INFUSE‘Œ_Bone_Graft/PEEK_Spacer/Anterior_Cervical_Plate,2,972,other_events,arm1,Historical Control,1,486
Drug_Hypersensitivity,Immune_system_disorders,NCT00485173,https://clinicaltrials.gov/show/NCT00485173,Degenerative_Disc_Disease,INFUSE‘Œ_Bone_Graft/PEEK_Spacer/Anterior_Cervical_Plate,2,972,serious_events,arm1,Historical Control,1,486
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00487188,https://clinicaltrials.gov/show/NCT00487188,HIV_Infections,Enfuvirtide|Highly_active_antiretroviral_treatment_(HAART)|,1,18,other_events,arm1,Induction Phase: HAART,1,18
Drug_hypersensitivity,Immune_system_disorders,NCT00488475,https://clinicaltrials.gov/show/NCT00488475,Rheumatoid_Arthritis,etanercept,3,9742,serious_events,arm0,Etanercept,2,4871
Drug_hypersensitivity,Immune_system_disorders,NCT00488475,https://clinicaltrials.gov/show/NCT00488475,Rheumatoid_Arthritis,etanercept,3,9742,other_events,arm0,Etanercept,1,4871
Drug_hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,22,139,other_events,arm6,Pemetrexed 500 + Carboplatin AUC 6 (Phase 2),17,66
Drug_hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,22,139,other_events,arm5,Pemetrexed 900 + Carboplatin AUC 6 (Phase 1),1,3
Drug_hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,22,139,serious_events,arm6,Pemetrexed 500 + Carboplatin AUC 6 (Phase 2),3,66
Drug_hypersensitivity,Immune_system_disorders,NCT00489359,https://clinicaltrials.gov/show/NCT00489359,Ovarian_Cancer|Primary_Peritoneal_Cancer|,Pemetrexed_-_Phase_1|Carboplatin_-_Phase_1|Pemetrexed_-_Phase_2|Carboplatin_-_Phase_2|,22,139,other_events,arm0,Pemetrexed 500 + Carboplatin AUC 5 (Phase 1),1,4
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00490646,https://clinicaltrials.gov/show/NCT00490646,Metastatic_Breast_Cancer,ixabepilone|docetaxel|trastuzumab|,2,24,other_events,arm0,Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV,2,24
Drug_Hypersensitivity,Immune_system_disorders,NCT00490139,https://clinicaltrials.gov/show/NCT00490139,Neoplasms_Breast,Lapatinib|Trastuzumab|,3,4118,serious_events,arm2,Lapatinib,2,2057
Drug_Hypersensitivity,Immune_system_disorders,NCT00490139,https://clinicaltrials.gov/show/NCT00490139,Neoplasms_Breast,Lapatinib|Trastuzumab|,3,4118,serious_events,arm0,Lapatinib plusTrastuzumab,1,2061
Drug_hypersensitivity,Immune_system_disorders,NCT00491608,https://clinicaltrials.gov/show/NCT00491608,Spinal_Surgery|Vascular_Surgery|,rThrombin,1,209,serious_events,arm0,rThrombin 1000 IU/mL,1,209
Drug_Hypersensitivity,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,27,172,other_events,arm0,Cediranib 20 mg,6,58
Drug_Hypersensitivity,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,27,172,other_events,arm1,Cediranib 30 mg,9,56
Drug_Hypersensitivity,Immune_system_disorders,NCT00494221,https://clinicaltrials.gov/show/NCT00494221,Metastatic_Colorectal_Cancer,AZD2171|FOLFOX_(5-fluorouracil_Leucovorin_Oxaliplatin)|Placebo_Cediranib|,27,172,other_events,arm2,Placebo,12,58
Drug_hypersensitivity,Immune_system_disorders,NCT00494091,https://clinicaltrials.gov/show/NCT00494091,Advanced_Renal_Cell_Carcinoma,Temsirolimus_(CCI-779)|Temsirolimus_(CCI-779)|,2,76,other_events,arm1,Temsirolimus 25 mg,2,76
Drug_Hypersensitivity,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,12,104,other_events,arm0,Vandetanib 100 mg Plus FOLFOX,3,32
Drug_Hypersensitivity,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,12,104,other_events,arm1,Vandetanib 300 mg Plus FOLFOX,4,35
Drug_Hypersensitivity,Immune_system_disorders,NCT00500292,https://clinicaltrials.gov/show/NCT00500292,Colorectal|Cancer|,Vandetanib|FOLFOX_regimen=oxaliplatin_fluorouracil_&_folinic_acid|,12,104,other_events,arm2,Placebo Plus FOLFOX,5,37
Drug_hypersensitivity,Immune_system_disorders,NCT00500357,https://clinicaltrials.gov/show/NCT00500357,Vaccines_Pneumococcal_Conjugate_Vaccine,13-valent_Pneumococcal_Conjugate_Vaccine,1,105,other_events,arm0,13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study),1,105
Drug_hypersensitivity,Immune_system_disorders,NCT00506441,https://clinicaltrials.gov/show/NCT00506441,Chronic_Kidney_Disease|Dialysis|Hyperphosphatemia|,MCI-196|Placebo|,1,245,other_events,arm0,MCI-196 (Open-label Period),1,245
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00509795,https://clinicaltrials.gov/show/NCT00509795,Macular_Degeneration,ranibizumab|aflibercept_injection_(VEGF_Trap-Eye_BAY86-5321)|aflibercept_injection_(VEGF_Trap-Eye_BAY86-5321)|aflibercept_injection_(VEGF_Trap-Eye_BAY86-5321)|,1,304,serious_events,arm0,Ranibizumab 0.5mg Q4,1,304
Drug_hypersensitivity,Immune_system_disorders,NCT00510068,https://clinicaltrials.gov/show/NCT00510068,Advanced_Neuroendocrine_Tumors_of_Pancreatic_Origin,Everolimus|Everolimus_Placebo|,1,203,serious_events,arm1,Placebo,1,203
Drug_Hypersensitivity,Immune_system_disorders,NCT00515086,https://clinicaltrials.gov/show/NCT00515086,Glioblastoma_Multiforme,Everolimus|Surgery|,1,6,other_events,arm0,Everolimus 10 mg + Surgery,1,6
Drug_hypersensitivity,Immune_system_disorders,NCT00519285,https://clinicaltrials.gov/show/NCT00519285,Prostatic_Neoplasms|Neoplasm_Metastasis|,Aflibercept|Placebo_(for_aflibercept)|Docetaxel|Prednisone_or_Prednisolone|,4,1209,serious_events,arm1,Aflibercept,3,611
Drug_hypersensitivity,Immune_system_disorders,NCT00519285,https://clinicaltrials.gov/show/NCT00519285,Prostatic_Neoplasms|Neoplasm_Metastasis|,Aflibercept|Placebo_(for_aflibercept)|Docetaxel|Prednisone_or_Prednisolone|,4,1209,serious_events,arm0,Placebo,1,598
Drug_hypersensitivity,Immune_system_disorders,NCT00520494,https://clinicaltrials.gov/show/NCT00520494,Common_Variable_Immunodeficiency|Agammaglobulinemia|,Vivaglobin,1,18,other_events,arm0,Vivaglobin,1,18
Drug_hypersensitivity,Immune_system_disorders,NCT00525148,https://clinicaltrials.gov/show/NCT00525148,Carcinoma_Non-Small-Cell_Lung,BIBW_2992,1,99,serious_events,arm1,Afatinib 50 mg,1,99
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,14,26352,serious_events,arm1,Vorapaxar,4,13186
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,14,26352,serious_events,arm0,Placebo,10,13166
Drug_hypersensitivity,Immune_system_disorders,NCT00528112,https://clinicaltrials.gov/show/NCT00528112,Contraception,LCS12|LCS16|,1,1432,serious_events,arm0,LCS12,1,1432
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00527943,https://clinicaltrials.gov/show/NCT00527943,Atherosclerosis|Myocardial_Ischemia|Myocardial_Infarction|,Vorapaxar|Placebo|,2,12887,serious_events,arm1,Vorapaxar,1,6446
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00527943,https://clinicaltrials.gov/show/NCT00527943,Atherosclerosis|Myocardial_Ischemia|Myocardial_Infarction|,Vorapaxar|Placebo|,2,12887,serious_events,arm0,Placebo,1,6441
Drug_hypersensitivity,Immune_system_disorders,NCT00529529,https://clinicaltrials.gov/show/NCT00529529,Asthma,Indacaterol_300_•_g|Salmeterol_50_•_g|Placebo_to_indacaterol|Placebo_to_salmeterol|,1,269,serious_events,arm2,Salmeterol 50 •_g,1,269
Drug_hypersensitivity,Immune_system_disorders,NCT00531427,https://clinicaltrials.gov/show/NCT00531427,Chronic_Pain|Osteoarthritis_of_the_Knee|,Buprenorphine|Placebo|,1,1151,serious_events,arm2,Open-label Run-in Period,1,1151
Drug_hypersensitivity,Immune_system_disorders,NCT00532155,https://clinicaltrials.gov/show/NCT00532155,Carcinoma|Non_Small_Cell_Lung|,Aflibercept_(ziv-aflibercept_AVE0005_VEGF_trap_ZALTRAP‘Œ)|Placebo|Docetaxel_(Taxotere‘Œ)|Dexamethasone_(pre-_and_post-medication_for_docetaxel)|,1,452,serious_events,arm1,Aflibercept/Docetaxel,1,452
Drug_hypersensitivity,Immune_system_disorders,NCT00535782,https://clinicaltrials.gov/show/NCT00535782,Rheumatoid_Arthritis,Tocilizumab|Placebo|Methotrexate|,1,130,serious_events,arm2,All TCZ + MTX,1,130
Drug_hypersensitivity,Immune_system_disorders,NCT00537329,https://clinicaltrials.gov/show/NCT00537329,Candidemia,Anidulafungin,1,43,other_events,arm0,Anidulafungin,1,43
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00538785,https://clinicaltrials.gov/show/NCT00538785,Congenital_Heart_Disease,Motavizumab|Palivizumab|,1,618,serious_events,arm0,Motavizumab (MEDI-524),1,618
Drug_hypersensitivity,Immune_system_disorders,NCT00540514,https://clinicaltrials.gov/show/NCT00540514,Non-Small_Cell_Lung_Carcinoma,Albumin-bound_paclitaxel|Paclitaxel|Carboplatin|,1,524,serious_events,arm1,Paclitaxel + Carboplatin,1,524
Drug_hypersensitivity,Immune_system_disorders,NCT00542386,https://clinicaltrials.gov/show/NCT00542386,Chronic_Kidney_Disease|Dialysis|Hyperphosphatemia|Dyslipidemia|,MCI-196|Placebo|,1,102,other_events,arm3,MCI-196: 12 g,1,102
Drug_hypersensitivity,Immune_system_disorders,NCT00543725,https://clinicaltrials.gov/show/NCT00543725,HIV_Infections|HIV-1|,TMC278|efavirenz|,1,340,serious_events,arm0,TMC278,1,340
Drug_hypersensitivity,Immune_system_disorders,NCT00545402,https://clinicaltrials.gov/show/NCT00545402,Liver_Transplantation,Mycophenolate_mofetil_adjusted_dose|Tacrolimus|Corticosteroids_IV|Mycophenolate_mofetil_Standard_dose|Corticosteroids_PO|,4,183,other_events,arm0,Adjusted MMF + Tacrolimus + CS,1,91
Drug_hypersensitivity,Immune_system_disorders,NCT00545402,https://clinicaltrials.gov/show/NCT00545402,Liver_Transplantation,Mycophenolate_mofetil_adjusted_dose|Tacrolimus|Corticosteroids_IV|Mycophenolate_mofetil_Standard_dose|Corticosteroids_PO|,4,183,other_events,arm1,Fixed-Dose MMF + Tacrolimus + CS,3,92
Drug_hypersensitivity,Immune_system_disorders,NCT00546572,https://clinicaltrials.gov/show/NCT00546572,Pneumococcal_Infections,13_valent_Pneumococcal_Conjugate_Vaccine|23vPS|,1,473,other_events,arm3,23vPS 6-M FU (Vax 1 / Year 0),1,473
Drug_hypersensitivity,Immune_system_disorders,NCT00549198,https://clinicaltrials.gov/show/NCT00549198,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir/lamivudine_and_efavirenz|Tenofovir/Emtricitabine_and_efavirenz|,6,385,serious_events,arm1,TDF/FTC FDC,1,193
Drug_hypersensitivity,Immune_system_disorders,NCT00549198,https://clinicaltrials.gov/show/NCT00549198,Infection_Human_Immunodeficiency_Virus_I|HIV_Infection|,Abacavir/lamivudine_and_efavirenz|Tenofovir/Emtricitabine_and_efavirenz|,6,385,serious_events,arm0,ABC/3TC FDC,5,192
Drug_hypersensitivity,Immune_system_disorders,NCT00549757,https://clinicaltrials.gov/show/NCT00549757,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|,Aliskiren|Placebo|,5,12330,serious_events,arm0,Core-phase: Aliskiren,2,4272
Drug_hypersensitivity,Immune_system_disorders,NCT00549757,https://clinicaltrials.gov/show/NCT00549757,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|,Aliskiren|Placebo|,5,12330,serious_events,arm2,Extension-phase: Aliskiren,2,3773
Drug_hypersensitivity,Immune_system_disorders,NCT00549757,https://clinicaltrials.gov/show/NCT00549757,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|,Aliskiren|Placebo|,5,12330,serious_events,arm1,Core-phase: Placebo,1,4285
Drug_hypersensitivity,Immune_system_disorders,NCT00551031,https://clinicaltrials.gov/show/NCT00551031,Influenza|Myxovirus_Infection|,Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|Split_Inactivated_Trivalent_Influenza_Vaccine|,1,320,serious_events,arm3,Fluzone‘Œ High Dose Group,1,320
Drug_hypersensitivity,Immune_system_disorders,NCT00552240,https://clinicaltrials.gov/show/NCT00552240,HIV_Infections,tenofovir_DF_300_mg_QD|tenofovir_DF_300_mg_QD|emtricitabine_200_mg_QD|emtricitabine_200_mg_QD|Nevirapine_200_mg_BID|Atazanavir_300_mg|Ritonavir_100_mg|,1,75,serious_events,arm0,Nevirapine (NVP) Plus Truvada,1,75
drug_hypersensitivity,Immune_system_disorders,NCT00553787,https://clinicaltrials.gov/show/NCT00553787,Obesity|Type_2_Diabetes|,VI-0521|VI-0521|VI-0521|,1,994,serious_events,arm2,VI-0521 Top,1,994
Drug_Hypersensitivity,Immune_system_disorders,NCT00556426,https://clinicaltrials.gov/show/NCT00556426,Pulmonary_Embolism|Venous_Thromboembolic_Disease|,Bard_Recovery_G2_Filter_System,1,100,other_events,arm0,All Patients Receiving the Filter,1,100
Drug_hypersensitivity,Immune_system_disorders,NCT00556998,https://clinicaltrials.gov/show/NCT00556998,Pharmacokinetics,Voriconazole,1,26,other_events,arm0,Voriconazole IV,1,26
Drug_hypersensitivity,Immune_system_disorders,NCT00560560,https://clinicaltrials.gov/show/NCT00560560,Colorectal_Neoplasm,CP-751_871,1,83,other_events,arm1,Figitumumab 30 mg/kg,1,83
Drug_hypersensitivity,Immune_system_disorders,NCT00561795,https://clinicaltrials.gov/show/NCT00561795,Primary_Peritoneal_Carcinoma|Tumor|Epithelial_Ovarian_Cancer|Uterine_Disease|Cervix_Diseases|Neoplasms_Ovarian|Cancer|,pazopanib_(GW786034)|carboplatin|paclitaxel|,1,6,other_events,arm1,10-Feb,1,6
Drug_hypersensitivity,Immune_system_disorders,NCT00561925,https://clinicaltrials.gov/show/NCT00561925,HIV_Infections,nevirapine_IR|nevirapine_XR|,1,1068,serious_events,arm0,NVP IR 200mg QD,1,1068
Drug_hypersensitivity,Immune_system_disorders,NCT00562484,https://clinicaltrials.gov/show/NCT00562484,Influenza,CSL_Limited_Influenza_Vaccine|Placebo|,1,5005,serious_events,arm1,Placebo,1,5005
Drug_hypersensitivity,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,6,804,serious_events,arm1,Placebo + Trastuzumab + Docetaxel,3,397
Drug_hypersensitivity,Immune_system_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,6,804,serious_events,arm0,Pertuzumab + Trastuzumab + Docetaxel,3,407
Drug_hypersensitivity,Immune_system_disorders,NCT00570713,https://clinicaltrials.gov/show/NCT00570713,Pancreatic_Cancer,MORAb-009|Placebo|Gemcitabine|,1,75,serious_events,arm1,Placebo Plus Gemcitabine (_„ƒPlacebo_„Ž),1,75
Drug_hypersensitivity,Immune_system_disorders,NCT00571649,https://clinicaltrials.gov/show/NCT00571649,Venous_Thromboembolism,Rivaroxaban_(Xarelto_BAY59-7939)|Enoxaparin|Rivaroxaban_placebo|Enoxaparin_placebo|,2,4001,serious_events,arm1,Enoxaparin,2,4001
Drug_hypersensitivity,Immune_system_disorders,NCT00574873,https://clinicaltrials.gov/show/NCT00574873,Chronic_Myeloid_Leukemia,Bosutinib|imatinib|,1,248,serious_events,arm0,Bosutinib,1,248
Drug_hypersensitivity,Immune_system_disorders,NCT00574548,https://clinicaltrials.gov/show/NCT00574548,Pneumococcal_Vaccines,13_valent_Pneumococcal_Conjugate_Vaccine|13_valent_Pneumococcal_Conjugate_Vaccine|13_valent_Pneumococcal_Conjugate_Vaccine|23-valent_Pneumococcal_Polysaccharide_Vaccine|23-valent_Pneumococcal_Polysaccharide_Vaccine|,2,383,other_events,arm7,13vPnC / 13vPnC: 6 Month Follow-up After Vax 2 (Year 1),1,160
Drug_hypersensitivity,Immune_system_disorders,NCT00574548,https://clinicaltrials.gov/show/NCT00574548,Pneumococcal_Vaccines,13_valent_Pneumococcal_Conjugate_Vaccine|13_valent_Pneumococcal_Conjugate_Vaccine|13_valent_Pneumococcal_Conjugate_Vaccine|23-valent_Pneumococcal_Polysaccharide_Vaccine|23-valent_Pneumococcal_Polysaccharide_Vaccine|,2,383,other_events,arm6,23vPS / 13vPnC (Year 1),1,223
Drug_hypersensitivity,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,5,394,other_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,4,197
Drug_hypersensitivity,Immune_system_disorders,NCT00577031,https://clinicaltrials.gov/show/NCT00577031,Colorectal_Cancer,bevacizumab_[Avastin]|Oxaliplatin|Xeloda|,5,394,serious_events,arm0,Bevacizumab+Oxaliplatin+Capecitabine/Bevacizumab,1,197
Drug_hypersensitivity,Immune_system_disorders,NCT00577863,https://clinicaltrials.gov/show/NCT00577863,Osteoporosis,teriparatide,2,199,other_events,arm0,Teriparatide,2,199
Drug_hypersensitivity,Immune_system_disorders,NCT00578786,https://clinicaltrials.gov/show/NCT00578786,Pulmonary_Arterial_Hypertension,ambrisentan,1,194,serious_events,arm2,Ambrisentan 10 mg,1,194
Drug_hypersensitivity,Immune_system_disorders,NCT00586469,https://clinicaltrials.gov/show/NCT00586469,Influenza|Influenza_Vaccines|,Fluviral,2,500,serious_events,arm1,New Bulk,2,500
Drug_hypersensitivity,Immune_system_disorders,NCT00590720,https://clinicaltrials.gov/show/NCT00590720,Asthma,MEDI528_50_mg|PLACEBO|,1,4,other_events,arm0,PLACEBO,1,4
Drug_hypersensitivity,Immune_system_disorders,NCT00603447,https://clinicaltrials.gov/show/NCT00603447,Relapsed_Multiple_Myeloma,Carfilzomib|Lenalidomide|Dexamethasone|,2,52,other_events,arm5,6: CFZ 20/27 mg/m‘_ + LEN 25 mg,1,8
Drug_hypersensitivity,Immune_system_disorders,NCT00603447,https://clinicaltrials.gov/show/NCT00603447,Relapsed_Multiple_Myeloma,Carfilzomib|Lenalidomide|Dexamethasone|,2,52,other_events,arm6,7: CFZ 20/27 mg/m‘_ + LEN 25 mg,1,44
Drug_hypersensitivity,Immune_system_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,1,7,other_events,arm5,Schedule B - CP-870893 0.2 mg/kg (Expansion Cohort),1,7
Drug_hypersensitivity,Immune_system_disorders,NCT00607724,https://clinicaltrials.gov/show/NCT00607724,Unspecified_Adult_Solid_Tumor_Protocol_Specific,GDC-0449,1,14,other_events,arm4,Stage 2: Basal Cell Carcinoma [GDC-0449 (270 mg)],1,14
Drug_hypersensitivity,Immune_system_disorders,NCT00609622,https://clinicaltrials.gov/show/NCT00609622,Colorectal_Neoplasms,sunitinib|mFOLFOX6|bevacizumab|mFOLFOX6|,1,96,serious_events,arm0,Sunitinib + mFOLFOX6,1,96
Drug_Hypersensitivity,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,49,422,serious_events,arm0,AZD0530  Paclitaxel  Carboplatin i.v.,4,105
Drug_Hypersensitivity,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,49,422,other_events,arm0,AZD0530  Paclitaxel  Carboplatin i.v.,16,105
Drug_Hypersensitivity,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,49,422,serious_events,arm1,Carboplatin Paclitaxel,5,106
Drug_Hypersensitivity,Immune_system_disorders,NCT00610714,https://clinicaltrials.gov/show/NCT00610714,Ovarian_Neoplasms|Ovarian_Cancer|,AZD0530|Carboplatin|Paclitaxel|,49,422,other_events,arm1,Carboplatin Paclitaxel,24,106
Drug_hypersensitivity,Immune_system_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,1,36,other_events,arm2,Axitinib + FOLFOX,1,36
Drug_Hypersensitivity,Immune_system_disorders,NCT00617669,https://clinicaltrials.gov/show/NCT00617669,Prostate_Cancer,Docetaxel|ZD4054|Placebo|,2,522,serious_events,arm0,ZD4054 + Docetaxel,2,522
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00618839,https://clinicaltrials.gov/show/NCT00618839,Third_Degree_Burn|Burns|Wound_Infection|Degloving_Injury|,StrataGraft_Skin_Tissue|Cadaver_allograft|,1,15,other_events,arm0,StrataGraft : Cadaver Allograft,1,15
Drug_hypersensitivity,Immune_system_disorders,NCT00622869,https://clinicaltrials.gov/show/NCT00622869,Liver_Transplantation,Tacrolimus_(reduced_tacrolimus)|Tacrolimus_(tacrolimus_elimination)|Tacrolimus_(tacrolimus_control)|Everolimus_(reduced_tacrolimus)|Everolimus_(tacrolimus_elimination)|Corticosteroids|,1,229,serious_events,arm1,Tacrolimus Elimination,1,229
Drug_hypersensitivity,Immune_system_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,1,393,serious_events,arm0,Bevacizumab+Temsirolimus,1,393
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00634088,https://clinicaltrials.gov/show/NCT00634088,Locally_Advanced_or_Metastatic_Breast_Cancer,Ixabepilone_32_mg/m^2_+_Lapatinib_1000_mg|Ixabepilone_32_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_40_mg/m^2_+_Lapatinib_1250_mg|Ixabepilone_+_Lapatinib_+_Capecitabine|,2,6,other_events,arm0,Ixabepilone 32 mg/m^2 + Lapatinib 1000 mg/d,2,6
Drug_hypersensitivity,Immune_system_disorders,NCT00636168,https://clinicaltrials.gov/show/NCT00636168,High_Risk_Stage_III_Melanoma,ipilimumab|Placebo|,1,471,serious_events,arm0,Ipilimumab 10mg/kg,1,471
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00643201,https://clinicaltrials.gov/show/NCT00643201,Venous_Thrombosis,Enoxaparin|warfarin|Placebo_for_apixaban|Placebo_for_enoxaparin|Placebo_for_warfarin|apixaban|,1,2689,serious_events,arm1,Enoxaparin/Warfarin,1,2689
Drug_hypersensitivity,Immune_system_disorders,NCT00644059,https://clinicaltrials.gov/show/NCT00644059,Influenza_Human,Adjuvanted_trivalent_inactivated_subunit_influenza_vaccine|Non-adjuvanted_trivalent_inactivated_subunit_influenza_vaccine_or_non-adjuvanted_trivalent_inactivated_split_influenza_vaccine|Meningococcal_C_conjugate_vaccine_or_tick-borne_encephalitis_vaccine|,1,607,serious_events,arm4,Non-Flu-control (TBE/Men C Vaccine),1,607
Drug_Hypersensitivity,Immune_system_disorders,NCT00653939,https://clinicaltrials.gov/show/NCT00653939,Tumors,Fosbretabulin|Carboplatin|Paclitaxel|Bevacizumab|,3,60,other_events,arm0,Arm 1: Chemotherapy+Bevacizumab,1,29
Drug_Hypersensitivity,Immune_system_disorders,NCT00653939,https://clinicaltrials.gov/show/NCT00653939,Tumors,Fosbretabulin|Carboplatin|Paclitaxel|Bevacizumab|,3,60,other_events,arm1,Arm 2: Active Comparator+Fosbretabulin,2,31
Drug_hypersensitivity,Immune_system_disorders,NCT00665431,https://clinicaltrials.gov/show/NCT00665431,Osteoarthritis,PN_400_(VIMOVO)|celebrex|Placebo|Rescue_Antacid|,1,245,serious_events,arm1,(Celebrex 200 mg Once Daily),1,245
Drug_hypersensitivity,Immune_system_disorders,NCT00666224,https://clinicaltrials.gov/show/NCT00666224,Multiple_Sclerosis,Glatiramer_Acetate_(DB)|Placebo|Glatiramer_Acetate_(OL)|,1,454,serious_events,arm2,Glatiramer Acetate (Entire Study),1,454
Drug_hypersensitivity,Immune_system_disorders,NCT00672958,https://clinicaltrials.gov/show/NCT00672958,Major_Depressive_Disorder,Vortioxetine|Placebo|,1,299,serious_events,arm1,Vortioxetine,1,299
Drug_hypersensitivity,Immune_system_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,1,289,other_events,arm0,Figitumumab + Erlotinib,1,289
Drug_hypersensitivity,Immune_system_disorders,NCT00676091,https://clinicaltrials.gov/show/NCT00676091,Vaccines_Pneumococcal_Conjugate_Vaccine,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnc)|,1,163,other_events,arm0,Infant Series 13vPnC,1,163
Drug_hypersensitivity,Immune_system_disorders,NCT00676520,https://clinicaltrials.gov/show/NCT00676520,Coronary_Artery_Disease,XIENCE_V‘Œ_Everolimus_Eluting_Coronary_Stent,1,4952,serious_events,arm0,Subjects Receiving the XIENCE V EECSS,1,4952
Drug_hypersensitivity,Immune_system_disorders,NCT00680901,https://clinicaltrials.gov/show/NCT00680901,Neoplasms_Gastrointestinal_Tract,Lapatinib|Placebo|Capecitabine|Oxaliplatin|,1,270,serious_events,arm0,CapeOx + Lapatinib,1,270
Drug_hypersensitivity,Immune_system_disorders,NCT00683800,https://clinicaltrials.gov/show/NCT00683800,Vasomotor_Symptoms,desvenlafaxine_succinate_(DVS)_SR|Placebo|,3,2118,other_events,arm0,DVS SR 100 mg,2,1066
Drug_hypersensitivity,Immune_system_disorders,NCT00683800,https://clinicaltrials.gov/show/NCT00683800,Vasomotor_Symptoms,desvenlafaxine_succinate_(DVS)_SR|Placebo|,3,2118,other_events,arm1,Placebo,1,1052
Drug_hypersensitivity,Immune_system_disorders,NCT00686543,https://clinicaltrials.gov/show/NCT00686543,Fungal_Infection|Acute_Myelogenous_Leukemia|Neutropenia|,Posaconazole,6,116,other_events,arm1,POS 200 mg TID on Days 9-15,1,21
Drug_hypersensitivity,Immune_system_disorders,NCT00686543,https://clinicaltrials.gov/show/NCT00686543,Fungal_Infection|Acute_Myelogenous_Leukemia|Neutropenia|,Posaconazole,6,116,other_events,arm0,POS 200 mg TID on Days 1-8,3,75
Drug_hypersensitivity,Immune_system_disorders,NCT00686543,https://clinicaltrials.gov/show/NCT00686543,Fungal_Infection|Acute_Myelogenous_Leukemia|Neutropenia|,Posaconazole,6,116,other_events,arm3,POS 400 mg TID on Days 9-15,2,20
Drug_Hypersensitivity,Immune_system_disorders,NCT00688545,https://clinicaltrials.gov/show/NCT00688545,Arthritis_Juvenile_Rheumatoid,Celecoxib|nsNSAIDs|,1,225,other_events,arm1,nsNSAIDs,1,225
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00689221,https://clinicaltrials.gov/show/NCT00689221,Glioblastoma,Cilengitide|Temozolomide|Radiotherapy|,1,263,serious_events,arm0,Cilengitide + Temozolomide + Radiotherapy,1,263
Drug_hypersensitivity,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,7,810,serious_events,arm1,Chemotherapy + Bevacizumab,6,401
Drug_hypersensitivity,Immune_system_disorders,NCT00700102,https://clinicaltrials.gov/show/NCT00700102,Colorectal_Cancer,Chemotherapy|Bevacizumab|,7,810,serious_events,arm0,Chemotherapy,1,409
Drug_hypersensitivity,Immune_system_disorders,NCT00699998,https://clinicaltrials.gov/show/NCT00699998,Acute_Coronary_Syndrome,Clopidogrel|Prasugrel|Commercially-available_Aspirin|,2,9240,serious_events,arm1,Clopidogrel,1,4617
Drug_hypersensitivity,Immune_system_disorders,NCT00699998,https://clinicaltrials.gov/show/NCT00699998,Acute_Coronary_Syndrome,Clopidogrel|Prasugrel|Commercially-available_Aspirin|,2,9240,serious_events,arm0,Prasugrel,1,4623
Drug_hypersensitivity,Immune_system_disorders,NCT00702520,https://clinicaltrials.gov/show/NCT00702520,Pregnancy|Neonates|,Corifollitropin_alpha_(MK-8962_Org_36286)_100_ug|Corifollitropin_alpha_(MK-8962_Org_36286)_150_ug|Triptorelin|Recombinant_follicle_stimulating_hormone_(recFSH)|Human_chorionic_gonadotprophin_(hCG).|,1,11,other_events,arm3,Fetuses/Infants From Mothers Administered Cori. Alpha 150 ug,1,11
Drug_Hypersensitivity,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,14,302,other_events,arm2,Cetuximab+5-FU+Cisplatin,5,62
Drug_Hypersensitivity,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,14,302,serious_events,arm1,Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin,2,59
Drug_Hypersensitivity,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,14,302,serious_events,arm0,Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin,2,61
Drug_Hypersensitivity,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,14,302,other_events,arm0,Cilengitide 2000 mg Once Weekly+Cetuximab+5-FU+Cisplatin,3,61
Drug_Hypersensitivity,Immune_system_disorders,NCT00705016,https://clinicaltrials.gov/show/NCT00705016,Squamous_Cell_Cancer,Cilengitide_2000_mg_once_weekly|Cilengitide_2000_mg_twice_weekly|Cetuximab|5-fluorouracil_(5-FU)|Cisplatin|,14,302,other_events,arm1,Cilengitide 2000 mg Twice Weekly+Cetuximab+5-FU+Cisplatin,2,59
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00705614,https://clinicaltrials.gov/show/NCT00705614,Crohn's_Disease,Remicade,15,2662,serious_events,arm1,Remicade,11,1541
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00705614,https://clinicaltrials.gov/show/NCT00705614,Crohn's_Disease,Remicade,15,2662,serious_events,arm0,Standard Therapy,4,1121
Drug_hypersensitivity,Immune_system_disorders,NCT00716417,https://clinicaltrials.gov/show/NCT00716417,Neoplasms,BIBW_2992|BIBW_2992|,1,11,other_events,arm3,Pac175 + Cis75 + Afatinib40,1,11
Drug_hypersensitivity,Immune_system_disorders,NCT00717236,https://clinicaltrials.gov/show/NCT00717236,Rheumatoid_Arthritis,Certolizumab_pegol_(CZP)|Placebo|,1,846,serious_events,arm0,Certolizumab Pegol (CZP),1,846
Drug_hypersensitivity,Immune_system_disorders,NCT00722371,https://clinicaltrials.gov/show/NCT00722371,Type_2_Diabetes_Mellitus,Sitagliptin_phosphate|Pioglitazone_hydrochloride|Matching_placebo_to_sitagliptin|Matching_placebo_to_pioglitazone|Metformin|,1,230,serious_events,arm3,Pioglitazone 45 mg,1,230
Drug_hypersensitivity,Immune_system_disorders,NCT00725985,https://clinicaltrials.gov/show/NCT00725985,Multiple_Sclerosis,Cladribine|Cladribine|Placebo|Rebif‘Œ_new_formulation_(RNF)|,1,16,other_events,arm8,Placebo Rebif Cladribine 3.5 mg/kg (LTFU),1,16
Drug_hypersensitivity,Immune_system_disorders,NCT00737048,https://clinicaltrials.gov/show/NCT00737048,Pain|Postoperative_Pain|,Tramadol_Hydrochloride|Acetaminophen|Placebo|Tramadol_plus_Acetaminophen|,1,130,serious_events,arm2,Acetaminophen and Placebo,1,130
Drug_hypersensitivity,Immune_system_disorders,NCT00737100,https://clinicaltrials.gov/show/NCT00737100,Cystic_Fibrosis,Placebo_Respimat|Tiotropium_bromide_5_mcg|tiotropium_bromide-low_dose-2.5mcg|,1,166,serious_events,arm1,Tiotropium Respimat 2.5 Micrograms,1,166
Drug_hypersensitivity,Immune_system_disorders,NCT00739674,https://clinicaltrials.gov/show/NCT00739674,Hypertension,losartan_potassium_(+_hydrochlorothiazide_[HCTZ]_+_calcium_channel_blocker_[CCB])|Low_Salt_Diet|,3,531,other_events,arm0,Losartan-Based Regimen Alone (L Group),3,531
Drug_hypersensitivity,Immune_system_disorders,NCT00741338,https://clinicaltrials.gov/show/NCT00741338,Mucopolysaccharidosis_I,Laronidase|Cyclosporine_A_(CsA)|Azathioprine_(Aza)|,1,3,other_events,arm0,Cohort 1,1,3
Drug_hypersensitivity,Immune_system_disorders,NCT00744497,https://clinicaltrials.gov/show/NCT00744497,Prostatic_Neoplasms,Placebo|Dasatinib|Docetaxel|Prednisone|,2,761,serious_events,arm0,Dasatinib,2,761
Drug_hypersensitivity,Immune_system_disorders,NCT00748189,https://clinicaltrials.gov/show/NCT00748189,Leukaemia_Lymphocytic_Chronic,chlorambucil_tablets|ofatumumab_(GSK1841157)_infusion|,1,217,serious_events,arm1,Ofatumumab + Chlorambucil,1,217
Drug_hypersensitivity,Immune_system_disorders,NCT00761631,https://clinicaltrials.gov/show/NCT00761631,Healthy_Subjects,13_valent_pneumococcal_conjugate_vaccine,1,175,other_events,arm3,13vPnC Group 1 (Cohort 2) Dose 1,1,175
Drug_hypersensitivity,Immune_system_disorders,NCT00762034,https://clinicaltrials.gov/show/NCT00762034,Non-small_Cell_Lung_Cancer,Pemetrexed|Pemetrexed|Paclitaxel|Carboplatin|Bevacizumab|Bevacizumab|,1,443,serious_events,arm2,Pac/Carbo/Bev; Induction Phase,1,443
Drug_hypersensitivity,Immune_system_disorders,NCT00770146,https://clinicaltrials.gov/show/NCT00770146,Hypercholesterolemia|Coronary_Heart_Disease|,Mipomersen_sodium|Placebo|,1,105,other_events,arm1,Mipomersen,1,105
Drug_Hypersensitivity,Immune_system_disorders,NCT00771927,https://clinicaltrials.gov/show/NCT00771927,Epilepsies_Partial,Lacosamide,1,493,other_events,arm1,Other AED,1,493
Drug_hypersensitivity,Immune_system_disorders,NCT00777946,https://clinicaltrials.gov/show/NCT00777946,Hypertension,Aliskiren_300_mg|Aliskiren/Amlodipine_300/5_mg|Aliskiren/Amlodipine_300/10_mg|Placebo_to_Aliskiren|Placebo_to_Aliskiren/Amlodipine|,1,282,serious_events,arm0,Aliskiren 300 mg/Amlodipine 10 mg,1,282
Drug_hypersensitivity,Immune_system_disorders,NCT00778102,https://clinicaltrials.gov/show/NCT00778102,Colorectal_Cancer,5-FU|5-FU|5-FU|Irinotecan|Leucovorin|Leucovorin|Oxaliplatin|bevacizumab_[Avastin]|,1,37,serious_events,arm0,Bevacizumab + mFOLFOX-6,1,37
Drug_hypersensitivity,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,21,477,other_events,arm0,Cetuximab Plus FOLFIRI,1,101
Drug_hypersensitivity,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,21,477,other_events,arm1,Cetuximab Plus FOLFOX,17,188
Drug_hypersensitivity,Immune_system_disorders,NCT00778830,https://clinicaltrials.gov/show/NCT00778830,Metastatic_Colorectal_Cancer,Cetuximab|FOLFIRI|FOLFOX|,21,477,serious_events,arm1,Cetuximab Plus FOLFOX,3,188
drug_hypersensitivity,General_disorders,NCT00779259,https://clinicaltrials.gov/show/NCT00779259,Pharmacokinetics,Theophylline_300mg|Quinine_648_mg|Theophylline_300_mg|Quinine_648_mg|,1,24,serious_events,arm1,Quinine Alone,1,24
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,7,21026,serious_events,arm1,High Dose Edoxaban/Placebo Warfarin,3,7012
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,7,21026,serious_events,arm0,Warfarin/Placebo Edoxaban,3,7012
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,7,21026,serious_events,arm2,Low Dose Edoxaban/Placebo Warfarin,1,7002
Drug_hypersensitivity,Immune_system_disorders,NCT00783692,https://clinicaltrials.gov/show/NCT00783692,Crohn's_Disease,vedolizumab|Placebo|,1,153,serious_events,arm1,VDZ/PBO,1,153
Drug_hypersensitivity,Immune_system_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,3,301,other_events,arm7,Period C - Zolpidem 5 or 10 mg,1,97
Drug_hypersensitivity,Immune_system_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,3,301,other_events,arm1,Period B - LY2624803 3 mg,1,113
Drug_hypersensitivity,Immune_system_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,3,301,other_events,arm8,Period D - LY2624803 1 mg,1,91
Drug_hypersensitivity,Immune_system_disorders,NCT00785577,https://clinicaltrials.gov/show/NCT00785577,Diabetic_Neuropathy_Painful,Placebo|Pregabalin|LY545694_21_mg|LY545694_49_mg|LY545694_105_mg|,1,43,other_events,arm1,LY545694 21 mg,1,43
Drug_hypersensitivity,Immune_system_disorders,NCT00787202,https://clinicaltrials.gov/show/NCT00787202,Ulcerative_Colitis,CP-_690_550|CP-_690_550|CP-_690_550|CP-_690_550|placebo|,1,33,serious_events,arm3,CP-690550 10 mg,1,33
Drug_hypersensitivity,Immune_system_disorders,NCT00787254,https://clinicaltrials.gov/show/NCT00787254,Stomach_Ulcer|Duodenal_Ulcer|,Lansoprazole|Gefarnate|,1,183,serious_events,arm0,Lansoprazole 15 mg QD,1,183
Drug_hypersensitivity,Immune_system_disorders,NCT00788957,https://clinicaltrials.gov/show/NCT00788957,Colon_Cancer|Colorectal_Cancer|Gastrointestinal_Cancer|Metastatic_Colorectal_Cancer|Rectal_Cancer|,Panitumumab|Ganitumab|Rilotumumab|Placebo|,1,11,other_events,arm0,Part 1: Panitumumab + Rilotumumab,1,11
Drug_hypersensitivity,Immune_system_disorders,NCT00792805,https://clinicaltrials.gov/show/NCT00792805,Chronic_Obstructive_Pulmonary_Disease_(COPD),Indacaterol_150_‘µg|Indacaterol_300_•_g|Placebo_to_indacaterol|,1,186,serious_events,arm2,Placebo to Indacaterol,1,186
drug_hypersensitivity,Immune_system_disorders,NCT00796367,https://clinicaltrials.gov/show/NCT00796367,Obesity,VI-0521|Placebo|VI-0521|,1,227,serious_events,arm0,Placebo,1,227
Drug_hypersensitivity,Immune_system_disorders,NCT00796757,https://clinicaltrials.gov/show/NCT00796757,Renal_Cell_Cancer,bevacizumab_[Avastin]|interferon_alfa-2a|,1,146,serious_events,arm0,Bevacizumab + Interferon,1,146
Drug_hypersensitivity,Immune_system_disorders,NCT00802360,https://clinicaltrials.gov/show/NCT00802360,Infertility,Menotropin|Progestrone_vaginal_insert|follitropin_beta|Progesterone_in_oil|Ganirelix|,1,42,other_events,arm2,Follistim/Endometrin,1,42
Drug_hypersensitivity,Immune_system_disorders,NCT00805142,https://clinicaltrials.gov/show/NCT00805142,Pain|Cancer|,Tapentadol_PR,1,42,serious_events,arm1,Opioid-Switch Participants (Tapentadol PR),1,42
Drug_hypersensitivity,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,4,1307,serious_events,arm0,Nintedanib Plus Docetaxel,2,652
Drug_hypersensitivity,Immune_system_disorders,NCT00805194,https://clinicaltrials.gov/show/NCT00805194,Carcinoma_Non-Small-Cell_Lung,placebo_plus_docetaxel|BIBF_1120_plus_docetaxel|,4,1307,serious_events,arm1,Placebo Plus Docetaxel,2,655
Drug_Hypersensitivity,Immune_system_disorders,NCT00809965,https://clinicaltrials.gov/show/NCT00809965,Acute_Coronary_Syndrome|Myocardial_Infarction|Myocardial_Ischemia|Unstable_Angina|,Rivaroxaban_2.5_mg|Rivaroxaban_5_mg|Placebo|Standard_of_care|,1,5125,serious_events,arm0,Placebo,1,5125
Drug_hypersensitivity,Immune_system_disorders,NCT00811018,https://clinicaltrials.gov/show/NCT00811018,Pulmonary_Arterial_Hypertension,Sitaxsentan,2,1192,serious_events,arm0,Sitaxsentan,2,1192
Drug_hypersensitivity,Immune_system_disorders,NCT00811954,https://clinicaltrials.gov/show/NCT00811954,HIV_Infection,Emtricitabine/tenofovir_disoproxil_fumarate|Raltegravir|Darunavir|Ritonavir|Atazanavir|,1,605,serious_events,arm0,Arm A: ATV/RTV + FTC/TDF,1,605
Drug_hypersensitivity,Immune_system_disorders,NCT00816166,https://clinicaltrials.gov/show/NCT00816166,Ischemic_Stroke|Transient_Ischemic_Attack|,Pharos_Vitesse_Neurovascular_Stent_System_(Stent_implantation)_+_Medical_therapy_(Aspirin_and_Clopidogrel)|Aspirin_and_Clopidogrel_(Medical_therapy)|,1,53,serious_events,arm1,Medical Therapy Group,1,53
Drug_hypersensitivity,Immune_system_disorders,NCT00820755,https://clinicaltrials.gov/show/NCT00820755,Non-Small_Cell_Lung_Cancer_(NSCLC),Cetuximab_plus_Platinum-based_Doublet_Chemotherapy|Cetuximab_500_mg/m^2|Cetuximab_250_mg/m^2|,8,583,serious_events,arm0,Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy,8,583
Drug_hypersensitivity,Immune_system_disorders,NCT00823212,https://clinicaltrials.gov/show/NCT00823212,Coronary_Artery_Disease,PROMUS_Coronary_Stent_System|PROMUS_Element_Coronary_Stent_System|Aspirin|Thienopyridine|,1,768,serious_events,arm1,PROMUS Element,1,768
Drug_hypersensitivity,Immune_system_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,2,87,other_events,arm2,Total Ofatumumab + Chemotherapy,1,61
Drug_hypersensitivity,Immune_system_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,2,87,other_events,arm0,Ofatumumab + DHAP,1,26
Drug_Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,13,1308,serious_events,arm1,Platinum Gemcitabine Cetuximab (Arm B),1,236
Drug_Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,13,1308,other_events,arm0,Paclitaxel Carboplatin Cetuximab (Arm A),6,235
Drug_Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,13,1308,other_events,arm1,Platinum Gemcitabine Cetuximab (Arm B),3,236
Drug_Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,13,1308,serious_events,arm0,Paclitaxel Carboplatin Cetuximab (Arm A),1,235
Drug_Hypersensitivity,Immune_system_disorders,NCT00828841,https://clinicaltrials.gov/show/NCT00828841,Non-Small_Cell_Lung_Cancer,Cetuximab|Paclitaxel|Carboplatin|Gemcitabine|Cisplatin|,13,1308,other_events,arm2,Platinum Pemetrexed Cetuximab (Arm C),1,130
Drug_hypersensitivity,Immune_system_disorders,NCT00831415,https://clinicaltrials.gov/show/NCT00831415,Major_Depressive_Disorder,desvenlafaxine_succinate_sustained_release_tablets,1,304,other_events,arm0,DVS SR,1,304
Drug_hypersensitivity,Immune_system_disorders,NCT00838097,https://clinicaltrials.gov/show/NCT00838097,Chronic_Kidney_Disease,Null,1,319,other_events,arm0,Darbepoetin Alfa,1,319
Drug_Hypersensitivity,Immune_system_disorders,NCT00839800,https://clinicaltrials.gov/show/NCT00839800,Asthma,Symbicort_Turbuhaler|Terbutaline_Turbuhaler|,1,1042,serious_events,arm1,Symbicort+Terbutaline As Needed,1,1042
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00842712,https://clinicaltrials.gov/show/NCT00842712,Carcinoma_Non-Small-Cell_Lung,Cilengitide|Cilengitide|Cetuximab|Cisplatin|Cisplatin|Gemcitabine|Vinorelbine|Cilengitide|Cilengitide|Cetuximab|Chemotherapy|,1,85,serious_events,arm4,Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy,1,85
Drug_hypersensitivity,Immune_system_disorders,NCT00845728,https://clinicaltrials.gov/show/NCT00845728,Chronic_Obstructive_Pulmonary_Disease,Indacaterol_150_‘µg|Tiotropium|,1,1721,serious_events,arm0,IndIndacaterol,1,1721
Drug_hypersensitivity,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,13,354,serious_events,arm1,mFOLFOX6 + Aflibercept,3,119
Drug_hypersensitivity,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,13,354,other_events,arm0,mFOLFOX6 Only,6,116
Drug_hypersensitivity,Immune_system_disorders,NCT00851084,https://clinicaltrials.gov/show/NCT00851084,Colorectal_Neoplasms|Neoplasm_Metastasis|,aflibercept|oxaliplatin|5-FU|Folinic_Acid|,13,354,other_events,arm1,mFOLFOX6 + Aflibercept,4,119
Drug_hypersensitivity,Immune_system_disorders,NCT00855582,https://clinicaltrials.gov/show/NCT00855582,Erectile_Dysfunction|Benign_Prostatic_Hyperplasia|,Tadalafil|Placebo|,1,198,other_events,arm0,Tadalafil 2.5 mg,1,198
Drug_hypersensitivity,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,2,226,other_events,arm0,Pem/Cis + Cet,1,113
Drug_hypersensitivity,Immune_system_disorders,NCT00867009,https://clinicaltrials.gov/show/NCT00867009,Non-Small-Cell_Lung_Cancer,Pemetrexed|Cisplatin|Cetuximab|,2,226,serious_events,arm0,Pem/Cis + Cet,1,113
Drug_hypersensitivity,Immune_system_disorders,NCT00866697,https://clinicaltrials.gov/show/NCT00866697,Neoplasms_Ovarian,Pazopanib|Placebo|,1,477,serious_events,arm1,Pazopanib 800 mg,1,477
Drug_hypersensitivity,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,15,172,other_events,arm0,Arm A - BelCaP,6,42
Drug_hypersensitivity,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,15,172,other_events,arm1,Arm B - CaP,5,44
Drug_hypersensitivity,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,15,172,serious_events,arm1,Arm B - CaP,2,44
Drug_hypersensitivity,Immune_system_disorders,NCT00873119,https://clinicaltrials.gov/show/NCT00873119,Carcinoma_of_Unknown_Primary,belinostat_carboplatin_paclitaxel|carboplatin_paclitaxel|,15,172,serious_events,arm0,Arm A - BelCaP,2,42
Drug_hypersensitivity,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,36,657,other_events,arm0,Bendamustine and Rituximab (BR),24,221
Drug_hypersensitivity,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,36,657,serious_events,arm0,Bendamustine and Rituximab (BR),4,221
Drug_hypersensitivity,Immune_system_disorders,NCT00877006,https://clinicaltrials.gov/show/NCT00877006,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,bendamustine|rituximab|vincristine|prednisone|cyclophosphamide|doxorubicin|,36,657,other_events,arm1,R-CHOP/CVP,8,215
Drug_hypersensitivity,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,2,38,other_events,arm4,Entire Study,1,20
Drug_hypersensitivity,Immune_system_disorders,NCT00884949,https://clinicaltrials.gov/show/NCT00884949,MPS_IV_A,BMN_110,2,38,other_events,arm2,2.0 mg/kg/Week,1,18
Drug_hypersensitivity,Immune_system_disorders,NCT00885755,https://clinicaltrials.gov/show/NCT00885755,Breast_Cancer,Standard_taxane_therapy|capecitabine_[Xeloda]|trastuzumab_[Herceptin]|,3,33,other_events,arm0,All Participants,3,33
Drug_hypersensitivity,Immune_system_disorders,NCT00889863,https://clinicaltrials.gov/show/NCT00889863,Systemic_Juvenile_Idiopathic_Arthritis_With_Active_Flare,canakinumab|placebo|,1,177,serious_events,arm0,Canakinumab: Part I,1,177
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,9,195,other_events,arm0,AZD8931 40 mg bd,1,6
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,9,195,other_events,arm5,Placebo + Paclitaxel,3,95
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,9,195,other_events,arm4,AZD8931 40MG bd + Paclitaxel,5,94
Drug_hypersensitivity,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,10,126,other_events,arm0,Nintedanib + mFolfox6,6,85
Drug_hypersensitivity,Immune_system_disorders,NCT00904839,https://clinicaltrials.gov/show/NCT00904839,Colorectal_Neoplasms,BIBF_1120|BIBF_1120|mFolfox|Bevacizumab|mFolfox_6|bevacizumab|,10,126,other_events,arm1,Bevacizumab + mFolfox6,4,41
Drug_hypersensitivity,Immune_system_disorders,NCT00905437,https://clinicaltrials.gov/show/NCT00905437,Pain_Perioperative,Placebo|Pregabalin|,1,37,other_events,arm1,Placebo,1,37
Drug_hypersensitivity,Immune_system_disorders,NCT00908037,https://clinicaltrials.gov/show/NCT00908037,Purpura_Thrombocytopaenic_Idiopathic,eltrombopag|Placebo|,2,65,other_events,arm3,Part 2/ 3 (Eltrombopag Open-Label Period),2,65
Drug_hypersensitivity,Immune_system_disorders,NCT00915278,https://clinicaltrials.gov/show/NCT00915278,Advanced_Non-Hematologic_Malignancies,PF-04605412,1,5,other_events,arm1,PF-04605412 11.25 mg,1,5
Drug_Hypersensitivity,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,34,232,other_events,arm1,Placebo+Paclitaxel+Carboplatin,10,58
Drug_Hypersensitivity,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,34,232,serious_events,arm1,Placebo+Paclitaxel+Carboplatin,4,58
Drug_Hypersensitivity,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,34,232,serious_events,arm0,ZD4054+Paclitaxel+Carboplatin,5,58
Drug_Hypersensitivity,Immune_system_disorders,NCT00929162,https://clinicaltrials.gov/show/NCT00929162,Patients_With_Advanced_Ovarian_Cancer_Sensitive_to_Platinum-based_Chemotherapy,ZD4054_Zibotentan|Paclitaxel|Carboplatin|Placebo|,34,232,other_events,arm0,ZD4054+Paclitaxel+Carboplatin,15,58
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT00932373,https://clinicaltrials.gov/show/NCT00932373,Metastatic_Breast_Cancer,trastuzumab-MCC-DM1,1,3,other_events,arm7,Trastuzumab-MCC-DM 1.6 mg/kg Weekly,1,3
Drug_hypersensitivity,Immune_system_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,6,76,other_events,arm2,Fludarabine/TST and Iodine I 131 TST (Combined Regimen),3,38
Drug_hypersensitivity,Immune_system_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,6,76,other_events,arm0,Fludarabine,3,38
Drug_hypersensitivity,Immune_system_disorders,NCT00961636,https://clinicaltrials.gov/show/NCT00961636,Dyslipidemia,ER_niacin_(+)_laropiprant_(ERN/LRPT)|ER_niacin_(+)_laropiprant_(ERN/LRPT)|Extended-release_niacin_(ERN)|Placebo_to_ERN/LRPT|,1,461,serious_events,arm0,ERN/LRPT,1,461
Drug_hypersensitivity,Immune_system_disorders,NCT00963235,https://clinicaltrials.gov/show/NCT00963235,HIV_Infections|Pneumococcal_Infections|,13-valent_pneumococcal_conjugate_vaccine|Blood_draw|,1,329,other_events,arm3,13vPnC (After Dose 3 Blood Draw),1,329
Drug_hypersensitivity,Immune_system_disorders,NCT00965848,https://clinicaltrials.gov/show/NCT00965848,Infection|Cross_Infection|Bacterial_Infections|Pneumonia_Ventilator-Associated|Intra-abdominal_Infections|Urinary_Tract_Infections|,Doripenem,1,107,other_events,arm0,Nosocomial Pneumonia,1,107
Drug_hypersensitivity,Immune_system_disorders,NCT00975130,https://clinicaltrials.gov/show/NCT00975130,Arthritis_Rheumatoid,SC_golimumab|IV_golimumab|,3,3357,serious_events,arm0,Golimumab 50 mg Subcutaneous (GLM50-SC),3,3357
Drug_hypersensitivity,Immune_system_disorders,NCT00986154,https://clinicaltrials.gov/show/NCT00986154,Venous_Thromboembolism|Deep_Vein_Thrombosis_(DVT)|Pulmonary_Embolism_(PE)|Thromboembolism|Venous_Thrombosis|,edoxaban_tosylate(DU-176b)|low_molecular_weight_heparin/unfractionated_heparin|warfarin|,2,8240,serious_events,arm0,Heparin/Edoxaban Tosylate,1,4118
Drug_hypersensitivity,Immune_system_disorders,NCT00986154,https://clinicaltrials.gov/show/NCT00986154,Venous_Thromboembolism|Deep_Vein_Thrombosis_(DVT)|Pulmonary_Embolism_(PE)|Thromboembolism|Venous_Thrombosis|,edoxaban_tosylate(DU-176b)|low_molecular_weight_heparin/unfractionated_heparin|warfarin|,2,8240,serious_events,arm1,Heparin/Warfarin,1,4122
Drug_Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,2,1046,serious_events,arm1,Lenalidomide/Docetaxel/Prednisone (DPL),1,525
Drug_Hypersensitivity,Immune_system_disorders,NCT00988208,https://clinicaltrials.gov/show/NCT00988208,Prostate_Cancer,Lenalidomide|Docetaxel|Prednisone|Placebo|,2,1046,serious_events,arm0,Docetaxel/Prednisone/Placebo (DP),1,521
Drug_Hypersensitivity,Immune_system_disorders,NCT00994318,https://clinicaltrials.gov/show/NCT00994318,Iron_Deficiency_Anaemia|Chronic_Kidney_Disease|,FCM_(Ferric_carboxymaltose)_high_ferritin_target|FCM_(Ferric_carboxymaltose)_low_ferritin_target|Oral_Iron_(Ferrous_sulphate)|,1,150,serious_events,arm1,FCM (Low Ferritin Target),1,150
Drug_hypersensitivity,Immune_system_disorders,NCT00996216,https://clinicaltrials.gov/show/NCT00996216,Hepatitis_C,Eltrombopag|Antiviral_therapy|,1,27,other_events,arm0,Eltrombopag (Part 1),1,27
Drug_hypersensitivity,Immune_system_disorders,NCT00997503,https://clinicaltrials.gov/show/NCT00997503,Coronary_Artery_Disease,TAXUS_LibertÍ©_Paclitaxel-Eluting_Coronary_Stent|prasugrel|placebo|aspirin|,23,8398,serious_events,arm0,TAXUS LibertÍ©: Overall Enrolled Population,4,4199
Drug_hypersensitivity,Immune_system_disorders,NCT00997503,https://clinicaltrials.gov/show/NCT00997503,Coronary_Artery_Disease,TAXUS_LibertÍ©_Paclitaxel-Eluting_Coronary_Stent|prasugrel|placebo|aspirin|,23,8398,other_events,arm0,TAXUS LibertÍ©: Overall Enrolled Population,19,4199
Drug_hypersensitivity,Immune_system_disorders,NCT01001221,https://clinicaltrials.gov/show/NCT01001221,Neoplasms_Malignant,cabazitaxel|gemcitabine|,1,6,other_events,arm3,Gemcitabine + Cabazitaxel Dose Level 0,1,6
Drug_hypersensitivity,Immune_system_disorders,NCT01004939,https://clinicaltrials.gov/show/NCT01004939,Thromboembolism|Venous_Thromboembolism|,fondaparinux,6,120,other_events,arm0,Fondaparinux - Mother,6,120
Drug_hypersensitivity,Immune_system_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,3,132,other_events,arm0,Cetuximab: Treatment Emergent Phase,1,66
Drug_hypersensitivity,Immune_system_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,3,132,serious_events,arm0,Cetuximab: Treatment Emergent Phase,2,66
Drug_hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,91,2704,other_events,arm0,Nintedanib,58,902
Drug_hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,91,2704,serious_events,arm0,Nintedanib,9,902
Drug_hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,91,2704,serious_events,arm1,Placebo,3,450
Drug_hypersensitivity,Immune_system_disorders,NCT01015118,https://clinicaltrials.gov/show/NCT01015118,Ovarian_Neoplasms|Peritoneal_Neoplasms|,Placebo|Paclitaxel|BIBF_1120|Carboplatin|Paclitaxel|Carboplatin|,91,2704,other_events,arm1,Placebo,21,450
Drug_hypersensitivity,Immune_system_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,3,4033,other_events,arm0,Non Pre-treatment,1,1996
Drug_hypersensitivity,Immune_system_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,3,4033,other_events,arm1,Pre-treatment,2,2037
Drug_hypersensitivity,Immune_system_disorders,NCT01020006,https://clinicaltrials.gov/show/NCT01020006,Pancreatic_Cancer|Ductal_Adrenocarcinoma|Exocrine_Pancreatic_Cancer|,PCI-27483|Gemcitabine|,1,18,other_events,arm1,(PCI-27483 + Gemcitabine)/Part B,1,18
Drug_hypersensitivity,Immune_system_disorders,NCT01026818,https://clinicaltrials.gov/show/NCT01026818,Erectile_Dysfunction,Tadalafil|Placebo|,1,139,serious_events,arm1,Tadalafil 5 mg OaD (Double-Blind Period/Washout Period),1,139
Drug_hypersensitivity,Immune_system_disorders,NCT01035255,https://clinicaltrials.gov/show/NCT01035255,Heart_Failure_With_Reduced_Ejection_Fraction,LCZ696_200_mg_BID|Enalapril_10_mg_BID|,6,8432,serious_events,arm1,Enalapril,5,4229
Drug_hypersensitivity,Immune_system_disorders,NCT01035255,https://clinicaltrials.gov/show/NCT01035255,Heart_Failure_With_Reduced_Ejection_Fraction,LCZ696_200_mg_BID|Enalapril_10_mg_BID|,6,8432,serious_events,arm0,LCZ696,1,4203
Drug_hypersensitivity,Immune_system_disorders,NCT01040689,https://clinicaltrials.gov/show/NCT01040689,Pulmonary_Disease_Chronic_Obstructive,Olodaterol_(BI1744)_Low|Placebo_(for_olodaterol_BI1744)|Placebo_(for_Tiotropium)|Olodaterol_(BI1744)_High|Tiotropium_18_mcg|,1,101,serious_events,arm3,Tiotropium (Tio) 18 mcg qd,1,101
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01040832,https://clinicaltrials.gov/show/NCT01040832,Squamous_Cell_Carcinoma_of_the_Head_and_Neck_Cancer,Cetuximab|EMD_1201081|,2,54,serious_events,arm0,Cetuximab Plus EMD 1201081,2,54
Drug_hypersensitivity,Immune_system_disorders,NCT01042977,https://clinicaltrials.gov/show/NCT01042977,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|Inadequate_Glycaemic_Control|,Dapagliflozin|Placebo|,1,482,serious_events,arm0,Dapagliflozin,1,482
Drug_hypersensitivity,Immune_system_disorders,NCT01056510,https://clinicaltrials.gov/show/NCT01056510,Lymphocytic_Leukemia_Chronic,bendamustine|chlorambucil|rituximab_[MabThera/Rituxan]|,1,177,serious_events,arm0,Rituximab + Bendamustine,1,177
Drug_hypersensitivity,Immune_system_disorders,NCT01059773,https://clinicaltrials.gov/show/NCT01059773,Psoriasis,Ustekinumab|Methotrexate|,1,245,serious_events,arm1,UST / MTX Gradually Withdrawn,1,245
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01071083,https://clinicaltrials.gov/show/NCT01071083,Relapsing_Remitting_Multiple_Sclerosis,natalizumab|interferon_beta_1-a|methylprednisolone|IV_placebo|glatiramer_acetate|,2,62,other_events,arm1,Natalizumab,1,45
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01071083,https://clinicaltrials.gov/show/NCT01071083,Relapsing_Remitting_Multiple_Sclerosis,natalizumab|interferon_beta_1-a|methylprednisolone|IV_placebo|glatiramer_acetate|,2,62,other_events,arm2,Interferon •_-1a,1,17
Drug_hypersensitivity,Immune_system_disorders,NCT01073163,https://clinicaltrials.gov/show/NCT01073163,Non-Hodgkin's_Lymphoma|Mantle_Cell_Lymphoma|,Bendamustine|Rituximab|,8,53,other_events,arm0,Bendamustine With Rituximab,8,53
Drug_hypersensitivity,Immune_system_disorders,NCT01072175,https://clinicaltrials.gov/show/NCT01072175,Cancer,GSK2118436|GSK1120212|,1,54,serious_events,arm7,Part C: Dabrafenib 150 mg + Trametinib 1 mg,1,54
drug_hypersensitivity,Immune_system_disorders,NCT01076452,https://clinicaltrials.gov/show/NCT01076452,Parkinson's_Disease,Bilateral_Deep_Brain_Stimulation,3,299,serious_events,arm0,Arm 1,2,147
drug_hypersensitivity,Immune_system_disorders,NCT01076452,https://clinicaltrials.gov/show/NCT01076452,Parkinson's_Disease,Bilateral_Deep_Brain_Stimulation,3,299,serious_events,arm1,Arm 2,1,152
Drug_hypersensitivity,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,7,75,other_events,arm0,Bevacizumab + Oxaliplatin + Capecitabine,2,25
Drug_hypersensitivity,Immune_system_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,7,75,other_events,arm1,Bevacizumab + FOLFOX,5,50
Drug_hypersensitivity,Immune_system_disorders,NCT01080391,https://clinicaltrials.gov/show/NCT01080391,Relapsed_Multiple_Myeloma,Dexamethasone|Lenalidomide|Carfilzomib|,1,392,serious_events,arm1,Carfilzomib Lenalidomide and Dexamethasone (CRd),1,392
Drug_hypersensitivity,Immune_system_disorders,NCT01081041,https://clinicaltrials.gov/show/NCT01081041,Head_and_Neck_Cancer,Cetuximab|Cisplatin|Carboplatin|5-Fluorouracil|,1,33,serious_events,arm0,Part 1: Safety Lead-In (Cetuximab Cis or Carbo 5-FU),1,33
Drug_Hypersensitivity,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,32,312,other_events,arm0,Olaparib/Carboplatin AUC4/Paclitaxel,15,81
Drug_Hypersensitivity,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,32,312,serious_events,arm0,Olaparib/Carboplatin AUC4/Paclitaxel,2,81
Drug_Hypersensitivity,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,32,312,other_events,arm1,Carboplatin AUC6/Paclitaxel,13,75
Drug_Hypersensitivity,Immune_system_disorders,NCT01081951,https://clinicaltrials.gov/show/NCT01081951,Ovarian_Cancer,olaparib|paclitaxel|carboplatin|paclitaxel|Drug:_carboplatin|,32,312,serious_events,arm1,Carboplatin AUC6/Paclitaxel,2,75
Drug_hypersensitivity,Immune_system_disorders,NCT01082640,https://clinicaltrials.gov/show/NCT01082640,Renal_Impairment,Febuxostat|Placebo|,2,32,other_events,arm1,Febuxostat 30 mg BID,2,32
Drug_hypersensitivity,Immune_system_disorders,NCT01085591,https://clinicaltrials.gov/show/NCT01085591,Clostridium_Difficile_Infection|Diarrhea|,CB-183315|Placebo|Vancomycin|,1,69,other_events,arm1,CB-183315 250 mg,1,69
Drug_hypersensitivity,Immune_system_disorders,NCT01087762,https://clinicaltrials.gov/show/NCT01087762,Spondyloarthropathies,CZP_200_mg_Q2W|CZP_400_mg_Q4W|Placebo|,1,107,serious_events,arm0,Placebo,1,107
Drug_hypersensitivity,Immune_system_disorders,NCT01088399,https://clinicaltrials.gov/show/NCT01088399,Hypopituitarism|Pituitary_Insufficiency|Growth_Hormone_Deficiency_Adult|,Somatropin_(rDNA_origin),2,9689,serious_events,arm1,Untreated,1,1269
Drug_hypersensitivity,Immune_system_disorders,NCT01088399,https://clinicaltrials.gov/show/NCT01088399,Hypopituitarism|Pituitary_Insufficiency|Growth_Hormone_Deficiency_Adult|,Somatropin_(rDNA_origin),2,9689,serious_events,arm0,Somatropin Treated,1,8420
Drug_hypersensitivity,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,13,288,other_events,arm3,Sequential Arm - Combination Therapy (Afa40+Ctx500),1,36
Drug_hypersensitivity,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,13,288,serious_events,arm1,Combination Arm - Afa40+Ctx500,3,126
Drug_hypersensitivity,Immune_system_disorders,NCT01090011,https://clinicaltrials.gov/show/NCT01090011,Carcinoma_Non-Small-Cell_Lung,Cetuximab|Cetuximab|BIBW_2992|BIBW_2992|,13,288,other_events,arm1,Combination Arm - Afa40+Ctx500,9,126
Drug_hypersensitivity,Immune_system_disorders,NCT01101841,https://clinicaltrials.gov/show/NCT01101841,Hot_Flashes,Brisdelle_(paroxetine_mesylate)|Placebo_capsules|,1,285,other_events,arm0,Brisdelle (Paroxetine Mesylate) Capsules,1,285
Drug_hypersensitivity,Immune_system_disorders,NCT01102972,https://clinicaltrials.gov/show/NCT01102972,Infection_Human_Immunodeficiency_Virus,Reyataz_+_Norvir_+_Truvada|Reyataz_+_Epzicom|,1,199,serious_events,arm0,ABC/3TC + ATV,1,199
Drug_hypersensitivity,Immune_system_disorders,NCT01106586,https://clinicaltrials.gov/show/NCT01106586,HIV|HIV_Infections|,Stribild|ATV/r_+_FTC/TDF|,1,353,serious_events,arm0,Stribild,1,353
Drug_hypersensitivity,Immune_system_disorders,NCT01106651,https://clinicaltrials.gov/show/NCT01106651,Diabetes_Mellitus_Type_2,Canagliflozin_100_mg|Canagliflozin_300_mg|Antihyperglycemic_agent(s)|Placebo|,1,237,serious_events,arm3,Placebo: Baseline to Week 104,1,237
Drug_hypersensitivity,Immune_system_disorders,NCT01107886,https://clinicaltrials.gov/show/NCT01107886,Type_2_Diabetes_Mellitus,Saxagliptin|Placebo|,8,16492,serious_events,arm0,Placebo,4,8212
Drug_hypersensitivity,Immune_system_disorders,NCT01107886,https://clinicaltrials.gov/show/NCT01107886,Type_2_Diabetes_Mellitus,Saxagliptin|Placebo|,8,16492,serious_events,arm1,Saxagliptin,4,8280
Drug_hypersensitivity,Immune_system_disorders,NCT01108341,https://clinicaltrials.gov/show/NCT01108341,Non-Hodgkin's_Lymphoma_(NHL),Bendamustine_hydrochloride|Ofatumumab|,5,49,other_events,arm0,Bendamustine and Ofatumumab,5,49
Drug_hypersensitivity,Immune_system_disorders,NCT01117012,https://clinicaltrials.gov/show/NCT01117012,Cystic_Fibrosis,Ivacaftor,4,384,serious_events,arm0,VX-770,1,192
Drug_hypersensitivity,Immune_system_disorders,NCT01117012,https://clinicaltrials.gov/show/NCT01117012,Cystic_Fibrosis,Ivacaftor,4,384,other_events,arm0,VX-770,3,192
Drug_hypersensitivity,Immune_system_disorders,NCT01119859,https://clinicaltrials.gov/show/NCT01119859,Rheumatoid_Arthritis,Tocilizumab|Adalimumab|Placebo_to_tocilizumab|Placebo_to_adalimumab|,1,162,serious_events,arm1,Adalimumab 40 mg,1,162
Drug_hypersensitivity,Immune_system_disorders,NCT01120379,https://clinicaltrials.gov/show/NCT01120379,Chronic_Coronary_Occlusion|Vascular_Disease|Myocardial_Ischemia|Coronary_Artery_Stenosis|Coronary_Disease|Coronary_Artery_Disease|Coronary_Restenosis|,XIENCE_V‘Œ_EECSS,3,4852,serious_events,arm0,XV-LTF Cohort,3,4852
Drug_hypersensitivity,Immune_system_disorders,NCT01120717,https://clinicaltrials.gov/show/NCT01120717,Chronic_Obstructive_Pulmonary_Disease,QVA149|Placebo|,1,225,serious_events,arm0,QVA149,1,225
Drug_hypersensitivity,Immune_system_disorders,NCT01121406,https://clinicaltrials.gov/show/NCT01121406,Ovarian_Neoplasms,Paclitaxel|Gemcitabine|Topotecan|Pegylated_liposomal_doxorubicin_(PLD)|BI_6727|,1,55,serious_events,arm1,Cytotoxic,1,55
Drug_hypersensitivity,Immune_system_disorders,NCT01124097,https://clinicaltrials.gov/show/NCT01124097,Post_Herpetic_Neuralgia,Eslicarbazepine_acetate_(BIA_2-093)|Placebo|,1,60,serious_events,arm0,Esl 1600 mg QD,1,60
Drug_hypersensitivity,Immune_system_disorders,NCT01126541,https://clinicaltrials.gov/show/NCT01126541,Rheumatoid_Arthritis,rituximab,1,81,other_events,arm2,Nonrandomized: Rituximab 1000 mg,1,81
Drug_hypersensitivity,Immune_system_disorders,NCT01126437,https://clinicaltrials.gov/show/NCT01126437,Pulmonary_Disease_Chronic_Obstructive,tiotropium_18_mcg|tiotropium_1.25_mcg_(2_actuations/day)|tiotropium_2.5_mcg_(2_actuations/day)|,2,11392,serious_events,arm1,Tiotropium 5 mcg and Placebo,1,5705
Drug_hypersensitivity,Immune_system_disorders,NCT01126437,https://clinicaltrials.gov/show/NCT01126437,Pulmonary_Disease_Chronic_Obstructive,tiotropium_18_mcg|tiotropium_1.25_mcg_(2_actuations/day)|tiotropium_2.5_mcg_(2_actuations/day)|,2,11392,serious_events,arm2,Tiotropium 18 mcg and Placebo,1,5687
Drug_hypersensitivity,Immune_system_disorders,NCT01129336,https://clinicaltrials.gov/show/NCT01129336,First_or_Second_Line_HER2-negative_Breast_Cancer|Metastatic_Disease_Without_Bone_Metastasis|,Zoledronic_acid|Standard_Therapy|,2,44,other_events,arm0,Patients Without Bone Metastases,1,15
Drug_hypersensitivity,Immune_system_disorders,NCT01129336,https://clinicaltrials.gov/show/NCT01129336,First_or_Second_Line_HER2-negative_Breast_Cancer|Metastatic_Disease_Without_Bone_Metastasis|,Zoledronic_acid|Standard_Therapy|,2,44,other_events,arm1,Patients With Bone Metastases,1,29
Drug_hypersensitivity,Immune_system_disorders,NCT01131507,https://clinicaltrials.gov/show/NCT01131507,Cystic_Fibrosis|Exocrine_Pancreatic_Insufficiency|,EUR-1008_(APT-1008),1,15,other_events,arm0,EUR-1008 (APT-1008),1,15
Drug_hypersensitivity,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,4,180,serious_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,1,90
Drug_hypersensitivity,Immune_system_disorders,NCT01135498,https://clinicaltrials.gov/show/NCT01135498,Colorectal_Cancer,bevacizumab_[Avastin]|eloxatin|capecitabine_[Xeloda]|erlotinib_[Tarceva]|,4,180,other_events,arm0,Bevacizumab+Eloxatin+Capecitabine/Bevacizumab+Erlotinib,3,90
Drug_hypersensitivity,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],7,334,other_events,arm0,Rituximab Induction (Induction Phase Only),6,233
Drug_hypersensitivity,Immune_system_disorders,NCT01144364,https://clinicaltrials.gov/show/NCT01144364,Non-Hodgkin's_Lymphoma,rituximab_[Mabthera/Rituxan],7,334,other_events,arm2,Rituximab Induction Observation Maintenance (Follow-up Phase),1,101
Drug_Hypersensitivity,Immune_system_disorders,NCT01145560,https://clinicaltrials.gov/show/NCT01145560,Severe_Sepsis|Septic_Shock|,AZD9773|Placebo|,1,100,serious_events,arm0,AZD9773 250/50 Units/kg,1,100
Drug_hypersensitivity,Immune_system_disorders,NCT01147302,https://clinicaltrials.gov/show/NCT01147302,Graft_Rejection,Placebo|C1_Esterase_Inhibitor_(Human)|,1,9,other_events,arm1,CINRYZE,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT01162122,https://clinicaltrials.gov/show/NCT01162122,Influenza,MF59_adjuvanted_trivalent_subunit_influenza_vaccine_(aTIV)|Non-adjuvanted_trivalent_subunit_influenza_vaccine_(TIV)|,1,3545,serious_events,arm0,aTIV (Pooled),1,3545
drug_hypersensitivity,Immune_system_disorders,NCT01167023,https://clinicaltrials.gov/show/NCT01167023,Sickle_Cell_Anemia,Prasugrel|Placebo|,1,19,other_events,arm0,Placebo,1,19
Drug_hypersensitivity,Immune_system_disorders,NCT01167881,https://clinicaltrials.gov/show/NCT01167881,Diabetes_Mellitus_Type_2,BI_10773|Glimepiride|Placebo|Placebo|,1,780,serious_events,arm1,Glimepiride,1,780
Drug_hypersensitivity,Immune_system_disorders,NCT01168349,https://clinicaltrials.gov/show/NCT01168349,Anemia_Neoplasms,epoetin_beta_[NeoRecormon],2,1789,other_events,arm2,Anemic Cancer Participants (Total Participants),1,1054
Drug_hypersensitivity,Immune_system_disorders,NCT01168349,https://clinicaltrials.gov/show/NCT01168349,Anemia_Neoplasms,epoetin_beta_[NeoRecormon],2,1789,other_events,arm0,Solid Tumor Participants,1,735
Drug_hypersensitivity,Immune_system_disorders,NCT01168973,https://clinicaltrials.gov/show/NCT01168973,Non-Small_Cell_Lung_Cancer,Ramucirumab|Placebo_(for_Ramucirumab)|Docetaxel|,3,1245,serious_events,arm0,Ramucirumab and Docetaxel,1,627
Drug_hypersensitivity,Immune_system_disorders,NCT01168973,https://clinicaltrials.gov/show/NCT01168973,Non-Small_Cell_Lung_Cancer,Ramucirumab|Placebo_(for_Ramucirumab)|Docetaxel|,3,1245,serious_events,arm1,Placebo and Docetaxel,2,618
Drug_hypersensitivity,Immune_system_disorders,NCT01169701,https://clinicaltrials.gov/show/NCT01169701,Renal_Transplant,Everolimus|Tacrolimus|Mycophenolic_acid_(MPA)|,1,35,serious_events,arm1,Everolimus,1,35
Drug_hypersensitivity,Immune_system_disorders,NCT01175824,https://clinicaltrials.gov/show/NCT01175824,Diabetes_Mellitus_Type_2,Insulin_Lispro_Low_Mixture_(LM)|Insulin_Glargine|Prandial_Insulin_Lispro|,1,240,other_events,arm1,Insulin Glargine+Insulin Lispro,1,240
Drug_hypersensitivity,Immune_system_disorders,NCT01179347,https://clinicaltrials.gov/show/NCT01179347,Cystic_Fibrosis,tiotropium_Respimat‘Œ_inhaler|Placebo_Respimat‘Œ_inhaler|,1,147,serious_events,arm2,Placebo Randomized Group Over the Open__Label Period,1,147
Drug_hypersensitivity,Immune_system_disorders,NCT01183780,https://clinicaltrials.gov/show/NCT01183780,Colorectal_Cancer,Ramucirumab|Placebo|Irinotecan|Folinic_Acid|5-Fluorouracil|,1,528,serious_events,arm1,FOLFIRI + Placebo,1,528
Drug_hypersensitivity,Immune_system_disorders,NCT01187953,https://clinicaltrials.gov/show/NCT01187953,Renal_Failure,Prograf_(tacrolimus)|LCP-Tacro|,1,275,serious_events,arm1,Prograf (Tacrolimus),1,275
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01193348,https://clinicaltrials.gov/show/NCT01193348,Atypical_Hemolytic-Uremic_Syndrome,Eculizumab,1,22,other_events,arm0,Eculizumab,1,22
Drug_hypersensitivity,Immune_system_disorders,NCT01209624,https://clinicaltrials.gov/show/NCT01209624,Low_Tension_Glaucoma,Null,2,902,other_events,arm0,Xalatan‘Œ,2,902
Drug_hypersensitivity,Immune_system_disorders,NCT01212991,https://clinicaltrials.gov/show/NCT01212991,Prostate_Cancer,Enzalutamide|Placebo|,1,871,serious_events,arm0,Enzalutamide,1,871
Drug_hypersensitivity,Immune_system_disorders,NCT01225835,https://clinicaltrials.gov/show/NCT01225835,Infertility,Menotrophin|Follitrophin_alpha|Cetrorelix|Choriongonadotropin|Progesterone|,1,62,serious_events,arm0,Menotrophin,1,62
Drug_hypersensitivity,Immune_system_disorders,NCT01227824,https://clinicaltrials.gov/show/NCT01227824,Infection_Human_Immunodeficiency_Virus_I,GSK1349572_(dolutegravir)|raltegravir|GSK1349572_Placebo|ABC/3TC|TDF/FTC|raltegravir_Placebo|,3,411,serious_events,arm0,DTG 50 mg OD,3,411
Drug_hypersensitivity,Immune_system_disorders,NCT01230827,https://clinicaltrials.gov/show/NCT01230827,Juvenile_Idiopathic_Arthritis,CNTO_148_(Golimumab)|Placebo|Methotrexate|,1,66,serious_events,arm2,Group III: Placebo + MTX -> Golimumab 30 mg/m2 + MTX,1,66
Drug_hypersensitivity,Immune_system_disorders,NCT01232569,https://clinicaltrials.gov/show/NCT01232569,Rheumatoid_Arthritis,Tocilizumab_162_mg|Placebo|,1,437,serious_events,arm0,Tocilizumab Pre-filled Syringe,1,437
Drug_hypersensitivity,Immune_system_disorders,NCT01236391,https://clinicaltrials.gov/show/NCT01236391,Mantle_Cell_Lymphoma,PCI-32765,1,111,other_events,arm0,PCI-32765,1,111
Drug_hypersensitivity,Immune_system_disorders,NCT01242111,https://clinicaltrials.gov/show/NCT01242111,MPS_IV_A|Mucopolysaccharidosis_IVA|Morquio_A_Syndrome|,BMN_110,1,20,other_events,arm0,BMN 110,1,20
Drug_hypersensitivity,Immune_system_disorders,NCT01255761,https://clinicaltrials.gov/show/NCT01255761,Rheumatoid_Arthritis,Certolizumab_Pegol_(CZP),1,367,serious_events,arm1,CDAI to Assess Response to Cimzia,1,367
Drug_hypersensitivity,Immune_system_disorders,NCT01259713,https://clinicaltrials.gov/show/NCT01259713,Invasive_Fungal_Disease,Liposomal_amphotericin_B|Placebo|,1,237,serious_events,arm0,Liposomal Amphotericin B,1,237
Drug_hypersensitivity,Immune_system_disorders,NCT01260350,https://clinicaltrials.gov/show/NCT01260350,Chronic_Hepatitis_C_Infection,SOF|RBV|PEG|LDV|GS-9669|LDV/SOF|,1,10,other_events,arm5,Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3 TN,1,10
Drug_hypersensitivity,Immune_system_disorders,NCT01263015,https://clinicaltrials.gov/show/NCT01263015,Infection_Human_Immunodeficiency_Virus_I,Dolutegravir|Atripla|Abacavir/Lamivudine|Abacavir/Lamivudine_Placebo|Dolutegravir_placebo|Atripla_placebo|,1,414,serious_events,arm0,DTG 50 mg Plus ABC/3TC 600/300 mg Once Daily,1,414
Drug_hypersensitivity,Immune_system_disorders,NCT01263496,https://clinicaltrials.gov/show/NCT01263496,Type_2_Diabetes_Mellitus,Alogliptin|Alogliptin|Alogliptin|Alogliptin|Voglibose|,1,101,serious_events,arm1,Alogliptin 12.5 mg QD,1,101
Drug_hypersensitivity,Immune_system_disorders,NCT01272219,https://clinicaltrials.gov/show/NCT01272219,Metabolism_and_Nutrition_Disorder|Obesity|,liraglutide|placebo|placebo|liraglutide|placebo|,1,487,serious_events,arm1,Liraglutide Placebo no Pre-diabetes,1,487
Drug_hypersensitivity,Immune_system_disorders,NCT01277510,https://clinicaltrials.gov/show/NCT01277510,Chronic_Kidney_Disease|Hyperparathyroidism|Hyperparathyroidism_Secondary|Kidney_Disease|Secondary_Hyperparathyroidism|,cinacalcet_capsule|placebo|Standard_of_Care|,1,21,other_events,arm0,Double-blind Phase: Placebo,1,21
Drug_hypersensitivity,Immune_system_disorders,NCT01278394,https://clinicaltrials.gov/show/NCT01278394,Onychomycosis,AN2690_Solution_5.0_PERCENT,1,29,other_events,arm0,AN2690 Solution 5.0%,1,29
Drug_hypersensitivity,Immune_system_disorders,NCT01292135,https://clinicaltrials.gov/show/NCT01292135,B-cell_Chronic_Lymphocytic_Leukemia|Small_Lymphocytic_Lymphoma|,PCI-32765,2,30,other_events,arm0,PCI-32765 Plus Bendamustine/Rituximab (BR),2,30
Drug_Hypersensitivity,Immune_system_disorders,NCT01298531,https://clinicaltrials.gov/show/NCT01298531,Axial_Spondyloarthritis,etanercept|etanercept|placebo|,1,48,other_events,arm1,Placebo to Open Label ETN 50 mg Group,1,48
Drug_hypersensitivity,Immune_system_disorders,NCT01302860,https://clinicaltrials.gov/show/NCT01302860,Cryopyrin-associated_Periodic_Syndromes|Familial_Cold_Autoinflammatory_Syndrome|Muckle-Wells_Syndrome|Neonatal_Onset_Multisystem_Inflammatory_Disease|,ACZ885,1,17,other_events,arm0,Canakinumab,1,17
Drug_hypersensitivity,Immune_system_disorders,NCT01313624,https://clinicaltrials.gov/show/NCT01313624,Bronchiectasis,AZLI|Placebo|,1,134,serious_events,arm0,AZLI-AZLI (Double-Blind),1,134
Drug_hypersensitivity,Immune_system_disorders,NCT01317667,https://clinicaltrials.gov/show/NCT01317667,Ricin,RVEc,1,10,other_events,arm0,Group 1,1,10
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01336205,https://clinicaltrials.gov/show/NCT01336205,Opioid-Induced_Constipation_(OIC),NKTR-118|Usual_care|,1,270,serious_events,arm1,Usual Care,1,270
Drug_hypersensitivity,Immune_system_disorders,NCT01345682,https://clinicaltrials.gov/show/NCT01345682,Head_and_Neck_Neoplasms|Carcinoma_Squamous_Cell|,Afatinib|Methotrexate|,1,160,serious_events,arm1,Methotrexate,1,160
Drug_hypersensitivity,Immune_system_disorders,NCT01349907,https://clinicaltrials.gov/show/NCT01349907,Bipolar_Disorder,Asenapine|Rescue_medication|,1,81,serious_events,arm1,Placebo/Asenapine,1,81
Drug_hypersensitivity,Immune_system_disorders,NCT01352793,https://clinicaltrials.gov/show/NCT01352793,Meningitis_Meningococcal,rLP2086_vaccine|control|,1,3796,serious_events,arm0,Group 1: rLP2086,1,3796
Drug_hypersensitivity,Immune_system_disorders,NCT01362530,https://clinicaltrials.gov/show/NCT01362530,Chemotherapy_Induced_Nausea_and_Vomiting,Aprepitant_125_mg|Aprepitant_80_mg|Aprepitant_powder_for_suspension_(PFS)|Ondansetron|Placebo_for_Aprepitant_125_mg|Placebo_for_Aprepitant_80_mg|Placebo_for_Aprepitant_PFS|Emetogenic_chemotherapy|,1,152,serious_events,arm0,Aprepitant Regimen Cycle 1,1,152
Drug_hypersensitivity,Immune_system_disorders,NCT01369615,https://clinicaltrials.gov/show/NCT01369615,Pain,Oxycodone_hydrochloride_controlled-release_tablets,1,9,other_events,arm0,6 to < 12 Years,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT01376297,https://clinicaltrials.gov/show/NCT01376297,Chemotherapy-Induced_Nausea_and_Vomiting,Netupitant_and_Palonosetron|Aprepitant|Palonosetron|Dexamethasone|,1,308,serious_events,arm0,Netupitant and Palonosetron Plus Dexamethasone,1,308
Drug_hypersensitivity,Immune_system_disorders,NCT01379703,https://clinicaltrials.gov/show/NCT01379703,HIV-1_Patients,Null,6,3494,other_events,arm0,Total Study Population,3,2288
Drug_hypersensitivity,Immune_system_disorders,NCT01379703,https://clinicaltrials.gov/show/NCT01379703,HIV-1_Patients,Null,6,3494,other_events,arm1,Capsule Formulation,3,1206
Drug_hypersensitivity,Immune_system_disorders,NCT01381575,https://clinicaltrials.gov/show/NCT01381575,Infections_Papillomavirus,GSK_Biologicals'_HPV_vaccine_580299,1,415,serious_events,arm2,Cervarix 3 Group,1,415
Drug_hypersensitivity,Immune_system_disorders,NCT01419171,https://clinicaltrials.gov/show/NCT01419171,Atherosclerosis|Coronary_Artery_Disease|,OMEGA_ ¢_Monorail_Coronary_Stent_System,1,328,serious_events,arm0,OMEGA_ ¢ Monorail Coronary Stent System,1,328
Drug_hypersensitivity,Immune_system_disorders,NCT01419197,https://clinicaltrials.gov/show/NCT01419197,Breast_Cancer,Trastuzumab_emtansine|Treatment_of_physician's_choice|,1,184,serious_events,arm1,Treatment of Physician_„Žs Choice - Planned Treatment Period,1,184
Drug_hypersensitivity,Immune_system_disorders,NCT01444456,https://clinicaltrials.gov/show/NCT01444456,Anemia|Breast_Cancer|Cancer|Colorectal_Cancer|Lung_Cancer|Ovarian_Cancer|Prostate_Cancer|Solid_Tumors|Bladder_Cancer|Endometrial_Cancer|Renal_Cancer|Pancreatic_Cancer|Esophageal_Cancer|Gastric_Cancer|,Null,1,1158,other_events,arm0,Darbepoetin Alfa or Other ESA,1,1158
Drug_hypersensitivity,Immune_system_disorders,NCT01449929,https://clinicaltrials.gov/show/NCT01449929,Infection_Human_Immunodeficiency_Virus,dolutegravir_50_mg_OAD|darunavir_800mg_OAD|ritonavir_100mg_OAD|,1,242,serious_events,arm1,Darunavir 800 mg + Ritonavir 100 mg OD,1,242
Drug_hypersensitivity,Immune_system_disorders,NCT01453855,https://clinicaltrials.gov/show/NCT01453855,Open-Angle_Glaucoma|Ocular_Hypertension|,Travoprost_ophthalmic_solution_0.003_PERCENT|Travoprost_ophthalmic_solution_0.004_PERCENT|,1,421,serious_events,arm1,TRAVATAN,1,421
Drug_hypersensitivity,Immune_system_disorders,NCT01459653,https://clinicaltrials.gov/show/NCT01459653,Febrile_Neutropenia|Cancer|Breast_Cancer|Ovarian_Cancer|Lung_Cancer|Prostate_Cancer|Multiple_Myeloma|Bladder_Cancer|B-cell_Lymphoma|,Null,1,1496,serious_events,arm0,EP2006,1,1496
Drug_hypersensitivity,Immune_system_disorders,NCT01465958,https://clinicaltrials.gov/show/NCT01465958,Primary_Immunodeficiency,GAMUNEX-C|GAMUNEX-C|,2,23,other_events,arm0,Intravenous GAMUNEX-C,1,12
Drug_hypersensitivity,Immune_system_disorders,NCT01465958,https://clinicaltrials.gov/show/NCT01465958,Primary_Immunodeficiency,GAMUNEX-C|GAMUNEX-C|,2,23,other_events,arm1,Subcutaneous GAMUNEX-C,1,11
Drug_hypersensitivity,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,2,264,serious_events,arm0,Tivozanib + mFOLFOX6,1,177
Drug_hypersensitivity,Immune_system_disorders,NCT01478594,https://clinicaltrials.gov/show/NCT01478594,Colorectal_Cancer,Tivozanib|Bevacizumab|mFOLFOX6|,2,264,serious_events,arm1,Bevacizumab + mFOLFOX6,1,87
Drug_hypersensitivity,Immune_system_disorders,NCT01495702,https://clinicaltrials.gov/show/NCT01495702,Acquired_Immunodeficiency_Syndrome|HIV_Infections|,Stribild|FTC/TDF|NNRTI|,1,291,serious_events,arm0,Stribild,1,291
Drug_hypersensitivity,Immune_system_disorders,NCT01503021,https://clinicaltrials.gov/show/NCT01503021,End_Stage_Renal_Disease|Chronic_Kidney_Disease|,SFP|Placebo|,1,309,serious_events,arm2,Open-label Soluble Ferric Pyrophosphate,1,309
Drug_hypersensitivity,Immune_system_disorders,NCT01519674,https://clinicaltrials.gov/show/NCT01519674,Diabetes|Diabetes_Mellitus_Type_2|,biphasic_insulin_aspart_30|biphasic_insulin_aspart_30|sitagliptin|metformin|,1,192,serious_events,arm0,BID + Met,1,192
Drug_hypersensitivity,Immune_system_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,1,53,serious_events,arm1,Ofatumumab + Bendamustine 70 mg/m^2,1,53
Drug_hypersensitivity,Immune_system_disorders,NCT01526785,https://clinicaltrials.gov/show/NCT01526785,Pompe_Disease,Alglucosidase_alfa,2,113,other_events,arm0,Alglucosidase Alfa,2,113
Drug_hypersensitivity,Immune_system_disorders,NCT01555463,https://clinicaltrials.gov/show/NCT01555463,Papulopustular_Rosacea,Azelaic_acid_foam_15_PERCENT_(BAY39-6251)|Vehicle_foam|,1,484,other_events,arm0,Azelaic Acid Foam 15% (BAY39-6251),1,484
Drug_hypersensitivity,Immune_system_disorders,NCT01574651,https://clinicaltrials.gov/show/NCT01574651,Chronic_Obstructive_Pulmonary_Disease_(COPD),QVA149|Placebo_to_tiotropium|Placebo_to_formoterol|Tiotropium|Formoterol|Placebo_to_QVA149|,1,476,serious_events,arm0,QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol,1,476
Drug_hypersensitivity,Immune_system_disorders,NCT01591460,https://clinicaltrials.gov/show/NCT01591460,Hepatitis_C_Chronic,boceprevir|peginterferon_alfa-2a_[Pegasys]|peginterferon_alfa-2a_[Pegasys]|ribavirin_(Copegus]|ribavirin_(Copegus]|,1,144,serious_events,arm1,Noncirrhotics (Safety),1,144
Drug_hypersensitivity,Immune_system_disorders,NCT01594749,https://clinicaltrials.gov/show/NCT01594749,Chemotherapy-Induced_Nausea_and_Vomiting_(CINV),Fosaprepitant_dimeglumine|Fosaprepitant_Placebo|Dexamethasone|Ondansetron|Dexamethasone_Placebo|Ondansetron_Placebo|Rescue_Therapy|,1,504,serious_events,arm0,Fosaprepitant Regimen,1,504
Drug_hypersensitivity,Immune_system_disorders,NCT01597908,https://clinicaltrials.gov/show/NCT01597908,Melanoma,Dabrafenib|Vemurafenib|Trametinib|,1,349,serious_events,arm1,Vemurafenib,1,349
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01606137,https://clinicaltrials.gov/show/NCT01606137,Multiple_Sclerosis|Spasticity|Pain|,GW-1000-02,2,507,serious_events,arm0,GW-1000-02,2,507
Drug_hypersensitivity,Immune_system_disorders,NCT01621191,https://clinicaltrials.gov/show/NCT01621191,Fibromyalgia,Duloxetine,1,149,other_events,arm0,60 mg Duloxetine,1,149
Drug_hypersensitivity,Immune_system_disorders,NCT01648582,https://clinicaltrials.gov/show/NCT01648582,Type_2_Diabetes_Mellitus,Dulaglutide|Insulin_glargine|Metformin|Sulfonylureas|,1,257,other_events,arm2,Insulin Glargine,1,257
Drug_hypersensitivity,Immune_system_disorders,NCT01653158,https://clinicaltrials.gov/show/NCT01653158,Advanced_Non-Hematologic_Malignancies,CP-751871|Docetaxel|,1,19,other_events,arm7,CP-751871 20 mg/kg + Docetaxel,1,19
Drug_hypersensitivity,Immune_system_disorders,NCT01663714,https://clinicaltrials.gov/show/NCT01663714,Lymphoma_Non-Hodgkin,cycolophosphamide_vacristine_and_pednisone_(CVP)_x6_cycles_followed_by_tositumomab_and_iodine_I_131_tositumomab.,2,60,other_events,arm0,Period After CVP,1,30
Drug_hypersensitivity,Immune_system_disorders,NCT01663714,https://clinicaltrials.gov/show/NCT01663714,Lymphoma_Non-Hodgkin,cycolophosphamide_vacristine_and_pednisone_(CVP)_x6_cycles_followed_by_tositumomab_and_iodine_I_131_tositumomab.,2,60,other_events,arm2,Combined Regimen Period,1,30
Drug_hypersensitivity,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,5,59,other_events,arm0,Cohort 1: Blinatumomab 9/28/112 ‘µg/d,1,9
Drug_hypersensitivity,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,5,59,other_events,arm3,Cohort 1+3: Blinatumomab 9/28/112‘µg/d,1,23
Drug_hypersensitivity,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,5,59,other_events,arm4,Blinatumomab Overall,2,25
Drug_hypersensitivity,Immune_system_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,5,59,other_events,arm1,Cohort 2: Blinatumomab 112 ‘µg/d,1,2
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01766921,https://clinicaltrials.gov/show/NCT01766921,Pandemic_H5N1_Influenza,Adjuvanted_H5N1_pandemic_influenza_vaccine,2,2087,serious_events,arm2,Total,1,1388
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01766921,https://clinicaltrials.gov/show/NCT01766921,Pandemic_H5N1_Influenza,Adjuvanted_H5N1_pandemic_influenza_vaccine,2,2087,serious_events,arm0,High Dose,1,699
Drug_hypersensitivity,Immune_system_disorders,NCT01773473,https://clinicaltrials.gov/show/NCT01773473,Type_2_Diabetes_Mellitus,Insulin_Lispro_Mix25|Insulin_Lispro_Mix50|,1,207,other_events,arm0,Insulin Lispro Mix25,1,207
DRUG_HYPERSENSITIVITY,Immune_system_disorders,NCT01777763,https://clinicaltrials.gov/show/NCT01777763,Fungal_Infections,Posaconazole_200_mg|Posaconazole_300_mg|,1,210,serious_events,arm1,Posaconazole 300 mg,1,210
Drug_hypersensitivity,Immune_system_disorders,NCT01807923,https://clinicaltrials.gov/show/NCT01807923,Cystic_Fibrosis_Homozygous_for_the_F508del_CFTR_Mutation,Lumacaftor_Plus_Ivacaftor_Combination|Ivacaftor|Placebo|,1,182,serious_events,arm2,LUM 400 mg q12h/ IVA 250 mg q12h,1,182
Drug_hypersensitivity,Immune_system_disorders,NCT01807949,https://clinicaltrials.gov/show/NCT01807949,Cystic_Fibrosis_Homozygous_for_the_F508del_CFTR_Mutation,Placebo|Lumacaftor_Plus_Ivacaftor_Combination|Ivacaftor|,1,187,other_events,arm2,LUM 400 mg q12h/ IVA 250 mg q12h,1,187
Drug_hypersensitivity,Immune_system_disorders,NCT01816295,https://clinicaltrials.gov/show/NCT01816295,Hypogonadism,Testosterone_Solution|Placebo_Solution|,2,914,other_events,arm2,Testosterone Solution - OLE,1,558
Drug_hypersensitivity,Immune_system_disorders,NCT01816295,https://clinicaltrials.gov/show/NCT01816295,Hypogonadism,Testosterone_Solution|Placebo_Solution|,2,914,other_events,arm0,Placebo Solution - Double Blind,1,356
Drug_Hypersensitivity,Immune_system_disorders,NCT01844895,https://clinicaltrials.gov/show/NCT01844895,Rheumatoid_Arthritis,Abatacept,2,234,other_events,arm1,Abatacept Cumulative (Prefilled Syringe and Autoinjector),1,117
Drug_Hypersensitivity,Immune_system_disorders,NCT01844895,https://clinicaltrials.gov/show/NCT01844895,Rheumatoid_Arthritis,Abatacept,2,234,other_events,arm0,Abatacept Via Autoinjector Only (Day 29 to End of Study),1,117
Drug_hypersensitivity,Immune_system_disorders,NCT01848990,https://clinicaltrials.gov/show/NCT01848990,Type_1_Diabetes_Mellitus,Commercial_Hylenex‘Œ_recombinant_(hyaluronidase_human_injection)|Precommercial_Hylenex_recombinant_(hyaluronidase_human_injection)|Insulin_lispro|Insulin_aspart|Insulin_glulisine|,2,227,other_events,arm0,Commercial Hylenex Recombinant (Formulation 1),2,227
Drug_hypersensitivity,Immune_system_disorders,NCT01952080,https://clinicaltrials.gov/show/NCT01952080,Short_Bowel_Syndrome,teduglutide,2,14,other_events,arm2,Teduglutide 0.025 mg/kg/Day,2,14
Drug_Hypersensitivity,Immune_system_disorders,NCT01964547,https://clinicaltrials.gov/show/NCT01964547,Multiple_Sclerosis|Spasticity|,Sativex|Placebo|,1,59,other_events,arm1,Placebo,1,59
Drug_hypersensitivity,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,28,224,other_events,arm0,Chemotherapy + Pertuzumab,11,75
Drug_hypersensitivity,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,28,224,other_events,arm1,Chemotherapy,13,74
Drug_hypersensitivity,Immune_system_disorders,NCT02004093,https://clinicaltrials.gov/show/NCT02004093,Ovarian_Cancer,pertuzumab|paclitaxel|gemcitabine|carboplatin|,28,224,serious_events,arm0,Chemotherapy + Pertuzumab,4,75
Drug_hypersensitivity,Immune_system_disorders,NCT02013817,https://clinicaltrials.gov/show/NCT02013817,Lymphocytic_Leukemia_Chronic,rituximab_[MabThera/Rituxan]|fludarabine|cyclophosphamide|,1,43,other_events,arm0,Rituximab Fludarabine Cyclophosphamide,1,43
Drug_hypersensitivity,Immune_system_disorders,NCT02015676,https://clinicaltrials.gov/show/NCT02015676,Breast_Cancer,trastuzumab|paclitaxel|Myocet|,1,69,other_events,arm0,Trastuzumab Doxorubicin Paclitaxel; Phase I & II,1,69
Drug_hypersensitivity,Immune_system_disorders,NCT02446990,https://clinicaltrials.gov/show/NCT02446990,Coronary_Artery_Disease.,Ivabradine|Placebo|,1,9544,serious_events,arm1,Placebo,1,9544